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Psoriasis is a chronic skin disease characterized by abnormal keratinocyte proliferation and 
differentiation, neoangiogenesis and inflammation. Its etiology is multifactorial, as both the 
environmental and genetic factors have an important role in the pathogenesis of psoriasis. 
The exact disease mechanism behind psoriasis still remains unknown. The most important 
genetic susceptibility region for psoriasis has been located to PSORS1 locus in 
chromosome 6. The area includes multiply good candidate genes but the strong linkage 
disequilibrium between them has made genetic studies difficult. One of the candidate genes 
in PSORS1 is CCHCR1, which has a psoriasis-associated gene form CCHCR1*WWCC. 
The aim of the study was to elucidate the function of CCHCR1 and its potential role in the 
pathogenesis of psoriasis. 
 
In this study, transgenic mice expressing either the healthy or psoriasis-associated gene 
form of CCHCR1 were engineered and characterized. Mice were phenotypically normal but 
their gene expression profiles revealed many similarities to that observed in human 
psoriatic skin. In addition, the psoriasis-associated gene form had specific impacts on the 
expression of many genes relevant to the pathogenesis of psoriasis. We also challenged the 
skin of CCHCR1 transgenic mice with wounding or 12-O-tetradecanoylphorbol-13-acetate 
(TPA). The experiments revealed that CCHCR1 impacts on keratinocyte proliferation by 
limiting it. In addition, we demonstrated that CCHCR1 has a role in steroidogenesis and 
showed that both CCHCR1 forms promote synthesis of steroids. Also many agents relevant 
either for steroidogenesis or cell proliferation were shown to regulate the expression level 
of CCHCR1. 
 
The present study showed that CCHCR1 has functional properties relevant in the context of 
psoriasis. Firstly, CCHCR1 affects proliferation of keratinocytes as it may function as a 
negative regulator of keratinocyte proliferation. Secondly, CCHCR1 also has a role in 
steroidogenesis, a function relevant both in the pathogenesis of psoriasis and regulation of 
cell  proliferation.  This  study  suggests  that  aberrant  function  of  CCHCR1  may  lead  to  






Psoriasis is a chronic inflammatory skin disease affecting 1-3% of Caucasians. Psoriasis is 
characterized by red well-defined skin plaques which are typically located on the scalp, 
knees or elbows. The molecular level pathogenesis of psoriasis is still poorly understood. 
The main histological features observed in psoriatic skin are the hyperproliferation and 
impaired differentiation of keratinocytes, infiltration of inflammatory cells and vascular 
changes. The disease lessens the quality of life and in addition, it also predisposes to other 
chronic diseases, including type II diabetes and cardiovascular diseases. There is no 
curative treatment available for psoriasis and the current psoriasis treatments may cause 
significant side effects.  
 
Psoriasis is a multifactorial disease, as both environmental and genetic factors are needed 
for disease onset. The major susceptibility locus for psoriasis, PSORS1, is located in the 
HLA-region on chromosome 6. PSORS1 includes multiple genes, of which three, HLA-C, 
corneodesmosin and Coiled-Coil -Helical Rod Protein 1, may be considered candidate 
genes for psoriasis. Strong linkage disequilibrium between the candidate genes has 
hindered the genetic studies aiming to identify the PSORS1 effector gene. Coiled-Coil -
Helical Rod Protein 1, also called CCHCR1, has altered expression in psoriatic skin and a 
psoriasis-associated risk allele CCHCR1*WWCC. 
 
The aims of this study were to investigate the biological role of CCHCR1 and its relevance 
in the pathogenesis of psoriasis using functional studies with mouse models and cultured 
keratinocytes. An important element of the study was the transgenic mice expressing either 
wild-type CCHCR1 or psoriasis-associated CCHCR1*WWCC form in their epidermis. In 
addition, the role of CCHCR1 as StAR-binding protein in steroidogenesis was elucidated. 
The functional studies of CCHCR1 support its role as an important PSORS1 effector gene. 
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REVIEW OF THE LITERATURE 
 
1. Clinical features of psoriasis 
 
Psoriasis is a chronic relapsing skin disease with wide variations in morphology of clinical 
lesions and course (Naldi&Gambini 2007). Characteristic for psoriasis are the red, well 
demarcated skin plaques, which vary in size and are covered by sheer scales (Lomholt 
1963). Both the environmental factors and suitable genetic background are needed for 
disease onset, making psoriasis an example of a multifactorial disease. 
1.1 Clinical subtypes of psoriasis 
 
Psoriasis vulgaris (PV)  is  the  most  common  type  of  psoriasis,  accounting  for  90  %  of  
psoriasis cases. In PV the plaques are red or pink, diverse in size and form and well-
outlined from the surrounding normal skin. Plaques are usually symmetrically distributed, 
located commonly on the extensor aspects of elbows and knees, and on the scalp (Lomholt 
1963). As PV includes different site-specific variants and forms, it is most probable that PV 
will turn out to be several closely-related, but still discrete, disease conditions with different 
phenotypic and genotypic characteristics. Different subtypes could explain the variability in 
the patients‘ responses to therapy, as is the case especially with the T lymphocyte-targeted 
biological agents (Griffiths&Barker 2007). 
 
Another  form of  psoriasis  is  guttate  psoriasis  (GP).  GP is  characterized  by  small  plaques  
over the upper trunk and proximal extremities. The plaques often emerge after a -
hemolytic streptococcal infection or viral infection. GP is most commonly seen in children 
or adolescents and is self-limiting, usually resolving within 3 to 4 months. However, a 
substantial portion of individuals with guttate psoriasis develop psoriasis vulgaris later  in  
their lives (Naldi et al. 2001). 
  
There are also other psoriasis subtypes, namely inverse, erythrodermic and pustular 
psoriasis. In addition also palmoplantar pustulosis (PPP), characterized by sterile pustules 
on the palms and soles, is still often described as a subtype of psoriasis. Although 25% of 
the PPP patients also have chronic plaque psoriasis, PPP has specific features when 
compared to PV. Although PV is equally common among men and women, PPP patients 
6 
are predominantly women. Also studies implicate that the genetic background behind PPP 
and  PV  is  different  (Asumalahti  et  al.  2003).  Rather  than  being  a  form  of  psoriasis,  PPP  
should be considered to show co-morbidity with PV. 
1.2 Prevalence 
 
Psoriasis  is  found  world-wide  and  its  prevalence  varies  from  0  %  to  11.8  %  in  different  
populations and ethnic groups (Gudjonsson&Elder 2007). The incidence is the highest 
among Caucasians and lowest among those of Japanese and African descent. Denmark and 
the Faroe Islands have the highest psoriasis prevalence in Europe, 2.9%, as the average 
psoriasis prevalence among Europeans, as well as Finns, is around 2% and 2.9% (Lomholt 
1963; Brandrup&Green 1981; Brandrup et al. 1982; Gudjonsson&Elder 2007). In the 
United States 2.2-2.6% of the population is affected with psoriasis. The prevalence varies 
between the ethnic groups in the US, as the incidence of psoriasis among African 
Americans is only 1.3%. This is in congruence with the fact that the prevalence of psoriasis 
among West Africans is only 0.3% and the ancestors of African Americans mostly 
originated from that area. There is also considerable difference between West and East 
African populations, as the psoriasis prevalence is almost 7 times higher in the eastern 
population (Gudjonsson&Elder 2007). The prevalence of psoriasis among Asian 
populations is rather low, only 0.3% (Yip 1984). Some populations, namely American 
Samoas and South American Indians, lack psoriasis completely (Gudjonsson&Elder 2007). 
Psoriasis incidence has increased significantly during the last three decades, but the reason 
behind this rise is still unknown (Icen et al. 2009). Latitude also affects psoriasis 
prevalence, probably through the beneficial effects of sunlight on psoriasis. Psoriasis affects 
men and women as often, even though there have been studies showing differences 
between the sexes (Braathen et al. 1989; Christophers 2001; Icen et al. 2009). 
1.3 Type I and II psoriasis  
 
Psoriasis has two subclasses based on age of onset and the presence of affected family 
members. The early onset group (type I) develops psoriasis before age 40, women slightly 
earlier than men. The mean age of onset is 33 years and 75% of the cases occur before age 
46 (Nevitt&Hutchinson 1996). In the late onset group (type II), the disease erupts 
substantially later, typically at the age of 57-60 years (Henseler&Christophers 1985; Smith 
et al. 1993). Subgroups differ also in the presence of the familial component. In the early 
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onset group, nearly half of the patients have an affected parent, whereas in the late onset 
group there is usually no family history of psoriasis present (Henseler&Christophers 1985). 
There are also different patterns in the HLA association: early onset psoriasis shows strong 
association with HLA-Cw6, whereas the late onset form has increased frequency of HLA-
Cw2 and HLA-B27 (Henseler 1997). It has indeed been shown that increasing age of onset 
correlates  with  diminishing  association  with  HLA-Cw6  on  chromosome  6  (Allen  et  al.  
2005).  There  are  also  differences  in  the  clinical  picture  between  the  groups,  as  the  early  
onset group has more a unstable and severe disease course when compared to the late onset 
type (Lomholt 1963; Stuart et al. 2002). 
1.4 Pathogenesis of psoriasis 
1.4.1 Epidermis 
 
Skin is composed of two layers, the outer epidermis and the inner dermis. The epidermal 
layer is composed of 10-20 layers of keratinocytes. Epidermal keratinocytes can be divided 
into four different layers according to the level of differentiation (Figure 1). The innermost 
layer, the basal layer (stratum basale) includes stem cells, which give rise to transiently 
amplifying keratinocytes. In the spinous layer (stratum spinosum), keratinocytes are 
connected by desmosomes and go through early differentiation, after which they will 
undergo apoptosis. In the granular layer (stratum granolosum) keratinocytes go through late 
and terminal differentiation and also lose their nuclei during this phase. Keratohyalin 
granules are found abundantly in the granular cells. In the outermost horny layer, 
keratinocytes die and form stratum corneum (Nemes&Steinert  1999).  In  healthy  skin,  the  
maturation of keratinocytes through the phases above usually takes 52-75 days. 
Keratinocytes  are  the  most  prevalent  cell  type  in  the  epidermis,  comprising  about  95  %.  
Also pigment-producing melanocytes, Lagerhans cells participating in antigen recognition, 
and receptors of touch, neuroendocrine Merkel cells, are found in the epidermis. Under the 
epidermis lies the connective tissue layer, the dermis, where blood vessels are also located 







Figure 1. Structure of epidermis. Keratinocytes form four layers based on level of 
differentiation (I=Stratum Corneum, II=Stratum Granolosum, III=Stratum Spinosum, 
IV=Stratum Basale). In addition to keratinocytes, other cell types found include 
melanocytes (V), Merkel cells and Lagerhans cells (VI). 
 
1.4.2 Psoriatic plaques 
 
As  the  disease  course  in  psoriasis  waxes  and  wanes,  the  histopathological  picture  of  the  
plaques (Figure 2) also varies according to the age of the lesions. In the early stages 
changes in the dermis dominate. These changes include minor superficial perivascular T-
lymphocyte infiltrate, followed by development of dilated blood vessels within dermal 
papillae and mild dermal edema. Also minor spongiosis with rare T lymphocyte and/or 
neutrophil extension into the epidermis can be observed in the earliest stage of psoriasis 
plaque. Intraepidermal T lymphocytes are predominantly CD8 positive. As the plaque 
develops, slight hyperplasia typical for psoriatic lesions is observed in the epidermis. The 
amount of neutrophils in the epidermis increases and parakeratosis also emerges. In the 
fully developed plaque, epidermal hyperplasia is notable, showing several typical features, 
including regular elongation of rete ridges with characteristic enlargement in their tips, 
reciprocal elongation of intervening dermal papillae with dilated and tortuous capillaries 
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and thinning of the epidermis above dermal papillae. Hyperkeratosis in the epidermis is 
prominent and its structure, with the alternating orthokeratosis and parakeratosis, suggests 
fluctuation in the epidermal growth activity in the lesion area. Vascular changes, namely 
increased vascularity, are also observed in the psoriatic plaques. Blood vessels in the 
dermal papillae are hyperplastic and hyperpermeable and show increased expression of E-
selectin, ICAM-1 and VCAM-1, in addition to elevated VEGF and VEDG receptor 
expression (Hvid et al. 2008). Neoangiogenesis can also be observed (Longo et al. 2002). 
Interestingly, keratinocytes produce angiogenic factors that promote abnormal dermal 
vascular proliferation and angiogenesis (Griffiths&Barker 2007). Plaques resolving or 
treated go through progressive reduction of parakeratosis and the number of neutrophils in 
the stratum corneum also decrease. The granular zone reforms and keratinocytes become 
orthokeratotic. Hyperplastic changes of the epidermis resolve later and also vascular 
changes recover slower (Murphy et al. 2007). 
 
 
Figure 2: Histology of healthy (A) and psoriatic (B) skin. Psoriatic skin shows epidermal 
acantohosis, elongation of rete ridges (indicated by arrows) with reciprocal elongation of 
intervening dermal papillae and inflammatory infiltrate (40X magnification). 
 
Psoriasis also causes alterations in epidermal keratin expression. The keratin expression in 
the basal layer is similar between the healthy and psoriatic skin as they both express K5 and 
K14 keratins. In healthy skin suprabasal keratinocytes express differentiation specific 
keratins 1 and 10, but in psoriatic suprabasal keratinocytes their expression is 
downregulated and hyperproliferative keratins 6 and 16 are expressed instead. In addition, 
keratin 17 expression is abundant in psoriatic lesions (Bonnekoh et al. 1995; Leigh et al. 
1995; Rao et al. 1996). 
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 An interesting aspect of the plaques is the chemical shield they offer. Psoriatic patients are 
quite resistant to infectious organisms and it has been argued that the compensatory 
response of immune system cells, together with abundant expression of genes responsible 
for the innate immunity, lie behind this divergent phenomenon (Buchau&Gallo 2007).  
Another interesting property of psoriatic plaques is that they only rarely associate with skin 
cancer (Nickoloff 2001). 
1.5 Features behind psoriasis 
 
Psoriasis is referred to as an autoimmune disease. This is based on the chronic 
inflammation and the absence of a pathogen or other foreign antigens causing the 
inflammation. Psoriasis is considered to be caused by a combination of genetic, 
immunological and environmental factors. Different kinds of environmental factors are 
known either to trigger the disease or to worsen its course. These include, for example, both 
physical and psychological stress, excessive alcohol intake and several drugs, such as 
lithium and beta-blockers (Dika et al. 2007). The formation of psoriasis plaque in response 
to cutaneous trauma, for example trauma from scratching or sunburn, is known as 
Koebner‘s phenomenon (Raychaudhuri et al. 2003). 
 
However, there is ongoing debate about the initial factors causing the disease and differing 
views are constantly coming forward. The question involving the initial factor or cell type 
behind  the  disease  has  focused  mainly  on  the  possible  roles  of  immune  system  cells  or  
keratinocytes in the initiation of pathogenesis. There is a convincing amount of data 
supporting both points of view. Aberrant keratinocyte metabolism as a primary cause 
behind the disease is based, among other things, on increased keratinocyte proliferation and 
an altered keratin expression profile in psoriatic lesions. The role of keratinocytes is also 
promoted by the fact that alterations in the expressions of intracellular signaling molecules 
exclusively in basal keratinocytes are capable of inducing skin inflammation similar to that 
observed in psoriasis. This observation is based on the Jun-B/c-jun double mutant mouse 
and corneodesmosin mouse (see section “Genetically engineered mouse models”), which 
develop skin disease resembling psoriasis (Zenz et al. 2005; Matsumoto et al. 2008). Most 
models  seem anyhow to  promote  the  idea  that  psoriasis  is  caused  by  abnormalities  in  the  
interaction between both keratinocytes and immune system cells, not in either of them 
alone (Ghoreschi et al. 2007). T lymphocytes are found in psoriatic lesions and T cell-
derived cytokines are also abundant in psoriatic skin, as well as numerous antigen-
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presenting cells producing inflammatory cytokines and chemokines (Buchau&Gallo 2007). 
Drugs modifying T lymphocyte functions have also been successfully used as psoriasis 
treatment. Furthermore, bone marrow transplantation can affect psoriasis status: when a 
psoriatic patient has received a transplant from a healthy person, psoriatic lesions have 
healed.  The  phenomenon also  occurs  vice  versa  (Eedy et  al.  1990;  Gardembas-Pain  et  al.  
1990; Kanamori et al. 2002). In addition, the evidence gained with the immunodeficient 
SCID mouse model highlights the role of immunomechanisms in the pathogenesis of 
psoriasis: mice with grafted non-lesional skin from a psoriatic person develop psoriasis-like 
alterations to the transplanted skin after injection of autologous immunocytes. When the 
transplanted skin originated from a healthy person similar impact did not occur (Wrone-
Smith&Nickoloff 1996). The necessity of T lymphocytes can be questioned based on the 
Rag2-deficient Jun-B/c-jun double mutant mice. Mice develop a psoriasis-like condition 
with epidermal thickening, altered keratinocyte maturation and vascular changes in the 
absence of B and T cells (Zenz et al. 2005). In the absence of full mechanistic explanations 
more research is needed to conclude which cell type initiates pathogenesis of psoriasis. 
 
In addition, it is inadequate to consider psoriasis only as a disease of the skin as in fact, 
psoriasis is associated with many systemic disorders like Crohn’s disease, metabolic 
syndrome, type 2 diabetes and depression. The disease risk can also vary according to the 
severity  of  psoriasis.  This  is  seen  with  psoriasis  and  cardiovascular  disease:  patients  with  
mild psoriasis do not have increased risk, but if psoriasis is moderate or severe the relative 
risk for cardiovascular disease is almost three-fold. In addition, psoriasis associates with 
cancers such as lymphoma, but it remains unsolved whether the relation is with the disease 




Keratinocytes have a significant role in the formation of psoriasis plaque. Various types of 
alterations can be seen in the properties of keratinocytes in the plaques when compared to 
keratinocytes in healthy epidermis. Proliferation of keratinocytes is raised almost 50-fold 
but  the  factors  causing  the  increase  are  still  unknown  (Sabat  et  al.  2007).  There  are  two  
mechanisms that facilitate the increased proliferation. The cell cycle is considerably shorter 
in psoriatic keratinocytes compared to healthy keratinocytes (Ortonne 1999). In addition, 
the cell population participating in the accelerated cell cycle is greater in psoriatic 
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epidermis than that in healthy skin (Weinstein et al. 1985). Two possible sources for the 
increased dividing cell population have been proposed: the increased number of stem cells 
participating in cell divisions or the larger number of cell cycles that transiently amplifying 
cells go through before entering apoptosis. In addition to impaired proliferation, 
keratinocyte differentiation is also dysfunctional in psoriatic skin. Impaired differentiation 
results in parakeratosis and loss of the granular layer. The role of the keratinocytes in 
psoriasis is beyond doubt but the molecular mechanisms behind the alterations are still 
poorly understood. 
1.5.2 Inflammatory cells  
 
Inflammatory cells including T lymphocytes, neutrophils, mast cells, macrophages and 
dendritic cells are found in psoriasis plaques. The antigens or auto-antigens responsible for 
the inflammatory reaction have not been identified despite the vast amount of research. A 
self-peptide cross-reacting with streptococci is one of the candidates as streptococcal 
infections precede 90% of psoriasis type I cases (Ghoreschi et al. 2007). Dendritic cells 
(DC) act as antigen-presenting cells (APC) to initiate the immunoresponse after stimulation 
by  an  as  yet  unknown  signal.  Activated  DCs  migrate  to  lymphatic  tissue  and  secrete  
chemokines to attract naive T lymphocytes, which are then activated and differentiated to 
Th1 and Th17 type cells. Movement of the activated T lymphocytes from the periphery to 
the skin is elementary for the plaque to develop. The invasion is based on tissue-specific 
ligand receptor interaction and on that account skin homing T cells produce L-selectin, 
LFA-1 (lymphocyte function associated antigen 1) and CLA (cutaneous lymphocyte 
antigen) adhesion molecules. Resident skin cells also express molecules important in skin 
homing, including ICAM-1 (intercellular adhesion molecule 1) expressed by epidermal 
keratinocytes and E- and P-selectins in dermal capillaries. The initial interaction is formed 
between the L-selectin of T lymphocytes and E- and P-selectins expressed by vascular 
endothelial cells, after which other ligand-receptor interactions also emerge to continue the 
inflammation reaction. Both CD4 and CD8 positive T lymphocytes are in psoriasis plaque, 
CD8+ cells predominantly within the epidermis and CD4+ cells within the dermis. 
Especially the role of CD4+ cells is critical in the pathogenesis of psoriasis. Other 
inflammatory  cells  also  take  part  in  pathogenesis  but  their  role  is  not  as  well  understood.  
Both macrophages and mast cells produce cytokines including tumor necrosis factor (TNF), 
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interferon  (IFN- ) and interleukin 8 (IL-8), which are essential for psoriasis (Ghoreschi et 
al. 2007; Griffiths&Barker 2007; Nickoloff et al. 2007). 
1.5.3 Cytokines  
 
Immunocytes in skin communicate with other cells via production of cytokines and 
chemokines. Cytokines can influence various processes including cell proliferation, 
differentiation and inflammatory and anti-inflammatory reactions. In the pathogenesis of 
psoriasis, several cytokines form a complex network and it is unlikely that perturbations in 
the function of one of them would have causative effects on the disease course 
(Bonifati&Ameglio 1999). Nevertheless, it has been suggested that there are cytokines of 
primary and secondary importance when considering the impact of a single cytokine in the 
pathogenesis (Nickoloff et al. 2007). A substantial number of cytokines have been 
implicated in psoriasis. Psoriasis is commonly considered to be a Th1 type disease and 
cytokines of the pathway, including IL-2, IL-12, IFN-  and TNF- , are abundantly found in 
psoriasis plaques (Uyemura et al. 1993; Schlaak et al. 1994; Austin et al. 1999). 
Interleukin-2 is a T cell growth factor, which promotes T cell function, as well as stimulates 
natural killer cell activity, and promotes production of a wide variety of cytokines 
(Kemmett et al. 1990; Bonifati&Ameglio 1999; Gaspari 2006). Interferon  is an important 
immuneregulator and also has antiproliferative properties. Furthermore it can induce the 
expression of ICAM-1 in keratinocytes and endothelial cells and thus influence invasion of 
skin homing T lymphocytes in psoriatic skin (Griffiths et al. 1989). Tumor necrosis factor  
is produced by keratinocytes and has a focal role in skin inflammatory processes (Pietrzak 
et al. 2008). Proinflammatory cytokines IL-6 and IL-8, capable of promoting keratinocyte 
proliferation, are also expressed abundantly in psoriatic skin (Grossman et al. 1989; Tuschil 
et al. 1992). Recent additions to the list of cytokines relevant in psoriasis are IL-12 and IL-
23. In psoriatic skin IL-23 is overproduced by DCs and keratinocytes and promotes Th 17 
type T cells‘ survival and the production of IL-17 and IL-22, which are also considered to 
be significant in psoriasis (Fitch et al. 2007; Nickoloff et al. 2007). Interleukin 17 promotes 
accumulation of neutrophils, dendritic cells and T cells and also has an impact on barrier 
function. Interleukin-22 triggers keratinocyte hyperproliferation and downregulates genes 
associated with keratinocyte differentiation, which are functional aspects relevant for the 
pathogenesis of psoriasis (Chen et al. 2003; Nograles et al. 2008). Interleukin-12 
participates in several processes relevant for psoriasis including cell proliferation and 
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angiogenesis. It also promotes T lymphocyte activation and differentiation by promoting 
the Th1 pathway (Pietrzak et al. 2008). In addition to the aforementioned cytokines, other 
cytokines as well as chemokines are found and may have an impact on the pathogenesis of 
psoriasis. 
1.6 Current view of the psoriasis disease model 
 
According to Sabat et al., the development of psoriatic plaque begins with antigen 
recognition and uptake by antigen-presenting cells (APC) (Sabat et al. 2007). In psoriasis 
the dendritic cells (DC) are the most common type of antigen-presenting cells. Antigens are 
presented on the DC surface usually as MHC class II molecules, which can be recognized 
by T cell receptor of CD4+ T cells. In addition DCs can present antigens on MHC class I 
molecules, which lead to the activation of CD8+ T cells. DCs also enhance the production 
of adhesion and co-stimulatory molecules to facilitate its interaction with T cells. The 
antigens behind the process are not known (Sabat et al. 2007). 
  
Naive T cells have to go through maturation in lymphatic tissues. CD4+ T cells have a 
strong  affinity  to  MHC  II-peptide  complex  and  they  stick  together  by  forming  an  
immunological synapsis. Interaction between ICAM-1, produced by DCs, and LFA-1, from 
T cells, is one of the most important in order to facilitate the DC-T cell interaction. Naive T 
cells can mature either to Th1, Th2, Th17 or regulatory T cells and subtype is guided by the 
selection of a soluble mediator present during the activation of naive T cells. After the 
activation, T cells express cutaneous lymphocyte-associated antigen (CLA), which directs 
T cells to inflamed skin. P- and E-selectins expressed by endothelial cells are also important 
for T cell skin homing (Sabat et al. 2007). 
 
In inflamed skin, T cells enter the tissue and participate in the inflammation reaction. 
Interaction between P- and E- selectins and CLA, as well as other selectin ligands, facilitate 
leukocytes rolling along the blood vessel wall as they decrease the rolling velocity. 
Interestingly expressions of P- and E-selectins are upregulated in psoriatic skin, possibly 
stiffening the inflammation observed in psoriatic plaque. T cells recognize chemokines 
secreted by the endothelial cells, become active and a tight adhesion, facilitated by integrins 
produced by T cells and their ligands expressed by endothelial cells, is formed between the 
cells. The most important molecule in skin homing is LFA-1 binding to ICAM-2. T cells 
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probably enter the endothelial wall through pores formed between endothelial cells in an 
integrin-dependent process called diapedesis (Sabat et al. 2007). 
 
In the skin T cells are reactivated by different kinds of APCs, which also include 
keratinocytes. Interferon-  (IFN- ), produced by APCs, has an important role in T cell 
reactivation and proliferation. Interestingly, T cells in psoriatic skin have prolonged and 
increased IFN-  response when compared to healthy skin. Interferon-  enhances INF-  
expression in T cells. Also cytokines produced by APCs, especially IL-23 and IL-6, have an 
important role in reactivation. After reactivation T cells also express a variety of cytokines. 
T cell response leads to the activation of keratinocytes and the activation is carried out by 
Th17 and different cytokines produced by macrophages, DCs and keratinocytes themselves. 
Keratinocyte activation leads to their increased proliferation and alterations in the 
maturation process. In addition activated keratinocytes produce a vast variety of mediators, 
which further promote immigration of inflammatory cells and induce angiogenesis, thus 
enhancing phenomena relevant for the pathogenesis of psoriasis (Krueger, 2002; Sabat et 
al. 2007). 
1.7 Psoriasis treatments  
 
Psoriasis treatments include therapy with various topical agents, phototherapy and systemic 
treatments including biological agents. The selection of appropriate treatment depends on 
the severity and localization of the skin symptoms and the benefits and risks of different 
treatment options. Emotional impact of the disease is taken into consideration as well 
(Feldman et al. 2008). 
 
The major psoriasis treatments include topical corticosteroid and calcipotriol applications, 
photochemotherapy with psoralens and ultraviolet A (PUVA), phototherapy with ultraviolet 
B and systemic treatment with acitretin, methotrexate or cyclosporine. These treatments 
have a wide variety of well-known side effects such as fast relapse times, development of 
tolerance, sunburn reactions, impaired renal or liver function, teratogenicity and bone 
marrow suppression (Linden&Weinstein 1999). Psoriasis treatments affect T cell function, 
for example PUVA depletes lymphocytes, corticosteroids have immunosuppressive 
properties and cyclosporine has a major inhibitory effect on T cell activation. In addition 
cyclosporine has a strong antiproliferative effect on keratinocytes. Methotrexate also has a 
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similar kind of dual action, both in suppression of lymphocytes as well as in keratinocyte 
proliferation (Linden&Weinstein 1999; Krueger 2002). Newly developed biological 
psoriasis therapeutics are also targeted to T cell functions. They are a promising alternative 
to psoriasis treatment, with relatively good action and possibly milder side effects in some 
patients (Krueger 2002). One of the newly developed biological treatments is tumor 
necrosis factor (TNF)-blocking monoclonal antibodies (Rozenblit&Lebwohl 2009). Long 
term studies are still needed to ensure their efficacy and safety, but based on early studies 
antibody treatments blocking TNF seem to have great benefits. Despite the wide selection 
of psoriasis treatments, there is no curative treatment available for psoriasis at the moment 
(Linden&Weinstein 1999).  
 
2. Mouse models for psoriasis 
 
Animal models are highly important in the research of disease conditions. They facilitate a 
detailed study of the profound molecular mechanisms behind diseases and they are also 
used in the development of treatments. There are an extensive amount of aspects to take 
into account when thinking over the properties of a good animal model. To be a good 
model for psoriasis, the mouse model should manifest the key histological features 
observed in human psoriasis as well as the typical immunological reactions. A good model 
should  also  have  a  response  to  therapeutic  agents  similar  to  psoriatic  patients  
(Gudjonsson&Elder 2007; Danilenko 2008). In addition to humans, only rhesus monkeys 
develop chronic dermatitis resembling psoriasis both clinically and histopathologically 
(Lowe et al. 1981). Similar conditions have also been observed in other monkey species, 
dogs and pigs, but in these the occurrence is only sporadic (Boehncke&Schon 2007).  
 
There are many challenges in the development of a psoriasis mouse model because of the 
profound differences between human and mouse skin (Figure 3). These include the 
considerably difference in the size of the organism and fur covered skin of mouse with 
densely spread hair follicles as human skin is composed mostly of interfollicular areas. 
Human and mouse hair follicles differ also in gene expression profiles. In human skin there 
are differences in the gene expression observed in outer shoot sheath of the hair follicles 
and interfollicular areas as there is no similar phenomenon found in mouse skin. 
Interfollicular areas in mouse also lack rete ridges. In addition mouse skin is 75 % thinner 
than human skin and it is composed of only 2-3 keratinocyte layers. There are also 
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differences in the non-epithelial tissues. Human skin has a thicker dermis and only small 
cutaneous muscle rudiments in the face and neck whereas mice have a continuous 
cutaneous muscle layer. Mouse skin also recovers without scarring, indicating differences 
in wound healing processes. In addition many immunological aspects vary between human 
and mouse, mouse-specific dendritic and T cell subtypes as an example. Mice and humans 
also show differences in their genetic background since humans are outbred and laboratory 




Figure 3: Histology of mouse skin. Mouse skin has densely spread hair follicles, interfollicular areas 
have no rete ridges and the epidermis is composed of 2-3 keratinocyte layers (40X magnification). 
 
Absence of a suitable animal model has caused a great disadvantage for psoriasis research. 
However, various types of mouse models have been identified and developed, some 
showing more similarities to human psoriasis than others. It is notable that most of the mice 
presenting psoriasis-like features have not been developed in order to produce psoriasis 
mouse models but instead their psoriasis-like phenotype has evolved as a response to 
modifications done for other purposes. Mouse models can be divided into three groups: 







Table 1. Summary of various psoriasis mouse models and their characteristics relevant for the 




















Yes Yes HogenEsch et al. 1993;  
HogenEsch et al. 2001;  
Kim et al. 2002 
Flaky skin Yes Focal 
parakeratosis 
Yes Yes Sundberg et al. 1997 
Genetically modified 
models 
     
Targeted to 
 immune system 
     
K14-IL20 transgenic Yes Yes No No Blumberg et al. 2001 
K14-IL6 transgenic Yes No No No Turksen et al. 1992 
K14-p40 transgenic Yes No Yes Yes Kopp et al. 2001; 
Kopp et al. 2003 
 
Targeted to vascular 
endothelium 







Yes Unknown  
Detmar et al. 1998; 
 Xia et al. 2003 
       Tie 2 transgenic Yes Yes Yes Yes Voskas et al. 2005;  
Voskas et al. 2008 
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 epidermal   
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CDSN deletion Yes Yes Yes Yes Matsumoto et al. 2008;  
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2.1 Spontaneous mouse models 
 
The first potential animal models for psoriasis were mice with spontaneous mutations 
causing a psoriasis-form phenotype. Probably the best of the spontaneous models is “the 
flaky skin mouse” (Ttcfsn/ Ttcfsn), which shows enhanced proliferation and hyperkeratosis of 
stratified squamous epithelia, positive Koebner‘s phenomenon after tape stripping, 
intraepidermal invasion of neutrophils and an increased amount of epidermal growth factor 
receptors. However the pathogenesis behind these phenomena is unknown and the flaky 
skin mice do not express all the psoriatic features as both T cell infiltration and expression 
of hyperproliferative keratins is missing. Mice also have additional health problems 
independent from psoriasis. Another spontaneous model is the chronic proliferative 
dermatitis mouse (Sharpincpdm /Sharpincpdm). It develops eosinophilic inflammation in 
various tissues, including skin, leading to acanthosis. Deficiency of this model is the Th2-
driven inflammation, whereas inflammation in human psoriasis is Th1 and Th17-mediated. 
There are also other spontaneous mutations causing psoriasis-like phenotypes in mice. 
These animals often show characteristics typical for psoriatic dermis and epidermis. 
However, they generally lack T cell involvement, which is considered to be central in the 
pathogenesis of psoriasis (Gudjonsson et al. 2007; Danilenko 2008). 
2.2 Xenograft mouse models 
 
In xenograft models foreign skin is transplanted to an immunodeficient mouse. 
Transplanted skin can originate from a psoriatic patient and can be either non-lesional or 
lesional skin. Xenograft models are among the best animal models for psoriasis available at 
the moment as they can incorporate the genetic, phenotypical and immunopathological 
processes all relevant in psoriasis and are also considered to be the most faithful to human 
conditions. Xenograft models also have limitations: they are rather demanding to execute 
technically  and  also  the  supply  of  human psoriatic  skin  is  problematic  (Gudjonsson  et  al.  
2007; Danilenko 2008). 
 
A recent example of a xenograft model used in psoriasis research is the study of Stenderups 
et al. which  showed that  IL-20  has  a  critical  role  in  the  pathogenesis  of  psoriasis.  In  the  
study both plaque and non-lesional psoriatic skin samples were grafted on immunodeficient 
mice and the mice were treated either with recombinant human IL-20 or anti-IL-20 
20 
antibodies. They showed that blocking the IL-20 signaling induces resolution of psoriasis 
and also inhibits the onset of psoriasis. They also showed that IL-20 infusion, in addition to 
injection of non-activated leukocytes, promotes plaque formation in psoriatic non-lesional 
skin grafts (Stenderup et al. 2009). 
2.2.1 The nude mouse 
 
One of the xenograft models is the nude mouse, a mouse with a deficient thymus causing 
the incapability to produce mature T cells and resulting in impaired T cell function. The 
thymus deficiency, as well as disruption of normal hair growth, is caused by a mutation in  
FOXN1 (Forkhead box N1, aka WHN, winged helix nude) on chromosome 11 (Nehls et al. 
1994). It has been shown with the nude mouse that psoriatic features of a transplanted 
psoriatic plaque can be maintained even longer than two months without the presence of 
functional T cells (Boehncke&Schon 2007; Gudjonsson et al. 2007). 
2.2.2 The SCID mouse 
 
Another xenograft mouse model is the SCID mouse, which lacks both humoral and cellular 
immunity because of a mutation in a DNA-dependent protein kinase enzyme. The mutation 
causes defects in the antigen receptor gene rearrangements in lymphocytes and thus has an 
essential role in T and B cell development, causing severe combined immunodeficiency 
(SCID). The disadvantage of the SCID model is the variability of immunological properties 
between mouse lines with different genetical backgrounds. The phenotype is also 
reversible, reversibility depends on the mouse strain used and the age of the mice. Another 
disadvantage of the SCID mouse is the degradation of injected single cell suspensions. 
Because of this degradation this model is not well suited for studies including T cell 
engraftments. However, skin grafts are well preserved in SCID mouse (Boehncke&Schon 
2007; Gudjonsson et al. 2007). 
 
One of the interesting studies indicating the prominent role of T cells in the pathogenesis of 
psoriasis has been done with SCID mice. In the experiment autologous stimulated blood-
derived immunocytes from a psoriatic patient were injected under a non-lesional psoriatic 
skin transplant and the immunocytes were able to induce the conversion of the non-lesional 
skin to psoriatic plaque. If the transplanted skin originated from a healthy person, a similar 
effect was not observed (Wrone-Smith&Nickoloff 1996). 
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2.2.3 The Rag2/Rag1 mouse 
 
To obtain a mouse model with SCID-like phenotype without problems with the 
reversibility, deletion of recombinase-activating genes 1 and 2 (Rag1 and Rag2), 
participating in the development of the T and B cells, can be used (Boehncke&Schon 
2007). If deficiency in the innate immune system is also needed, SCID or Rag-deficient 
mice can be crossed with mice strains deficient in the innate immune system. This enhances 
tolerance to the xenografts. Another mice strain used in xenograft studies is AGR129, 
which is a triple mutant lacking both interferon type I and type II receptors, as well as 
Rag2, causing T and B cells to be lacking and immature natural killer cells with impaired 
cytotoxic activity. When psoriatic non-lesional skin was grafted to AGR129 mice, 90 % of 
the grafts spontaneously developed a psoriasis phenotype with the expansion of T cells 
within the graft. A similar reaction was not observed if the grafts originated from a healthy 
person (Boehncke&Schon 2007). 
2.3 Genetically engineered mouse models 
 
A wide variety of genetically engineered mice have been developed to facilitate psoriasis 
research including both the research of the disease mechanism behind the disease as well as 
development of new psoriasis treatments. Genetically engineered animals include both 
transgenic and knockout models and manifest some of the pathological features observed in 
psoriasis. Enhanced or reduced expression of specific genes is usually directed to the basal 
epidermis or suprabasal layer with specific keratin gene promoters. Promoters from keratin-
5 (KRT5) and keratin-14 (KRT14) direct the expression to the basal epidermis as keratin-1 
(KRT1), keratin-10 (KRT10) or involucrin promoters direct the expression to the 
suprabasal layer (Gudjonsson&Elder 2007). Genetically modified models include a wide 
spectrum of target genes (Table 1) and can be divided into three categories: modifications 
targeted to epidermal keratinocytes, leukocytes or vascular endothelium (Danilenko 2008). 
So far the best psoriasis models among genetically engineered mice are those with targeted 
mutations in keratinocytes and vascular endothelium. Mice with JunB/c-jun, Stat3, cdsn 
and Vegf mutations present many of the typical psoriatic features and most of all they all 
can develop lesions with psoriatic characteristics spontaneously without outside stimulus. 
Interestingly, genetic engineering attempts targeted at T cells have not been able to produce 
a mouse model representing hallmark features of psoriasis, despite the profound role T 
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lymphocytes have been proposed to have in immunological processes, participating in the 
pathogenesis of psoriasis. Hence, genetically modified mouse models developed so far 
emphasize the role of keratinocytes and vascular vessels in the multifactorial pathogenesis 
of psoriasis. 
2.3.1 c-Jun/JunB knockout mouse 
 
An example of a mouse model with modifications in epidermal keratinocytes is the c-
Jun/JunB knockout mouse. Jun proteins are part of the homo- or heterodimeric transcription 
factor complex AP-1, which also includes members from Fos, activating transcription 
factor (ATF) and musculoaponeutric fibrosarcoma (Maf) protein families (Eferl&Wagner 
2003). Jun family members, namely c-Jun (Jun), JunB and JunD, are important regulators 
of keratinocyte proliferation and differentiation and also have a profound role in cytokine 
production, all processes relevant for the pathogenesis of psoriasis (Zenz&Wagner 2006). 
Despite the high structural uniformity between the Jun proteins, they show significant 
differences in DNA binding activities and in transcriptional activation properties. C-Jun is 
regarded as a positive regulator of keratinocyte proliferation and differentiation through its 
direct effect on the expression level of epidermal growth factor receptor (EGFR). JunB 
antagonizes the effects of c-jun on proliferation. The DNA binding activity of AP-1 protein 
complexes is decreased in psoriatic plaques (Johansen et al. 2004). Interestingly, JunB gene 
is located to PSORS6 locus on chromosome 19p13. 
 
Zenz et al.have engineered JunB/c-jun deficient transgenic mice to study the effects of AP-
1 downregulation (Zenz et al. 2005). To avoid embryonic lethality due to AP-1 deletions 
(Zenz&Wagner 2006), studies were conducted in an inducible and conditional manner. 
Both JunB and c-Jun knockouts as well as double knockout including JunB/c-Jun were 
engineered, but only the double mutant showed spontaneous psoriasis phenotype emerging 
ten days after activation of the deletion. Mice skin presented the histological hallmarks of 
psoriasis, including a strongly thickened epidermis with prominent rete ridges, thickened 
keratinized upper layers with parakeratosis and increased supraepidermal vascularization. 
Also the immunological picture resembled that observed in psoriasis. In addition arthritic 
lesions resembling psoriasis arthritis were observed in the double mutant mice. Gene 
expression profiling revealed that the expression profile of the c-Jun/JunB mice resembled 
that observed in psoriatic cells. For example expression of chemotactic proteins S100A8 
and S100A9 was upregulated, and keratin 15 and caveolin expression was downregulated. 
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Upregulation of s100a8 and s100a9 was the first phenomenon observed in the pre-diseased 
skin. JunB/c-Jun deletions were also introduced to Rag-2 deficient mice and the phenotype 
was only slightly milder in the absence of functional T cells. Also the chemokine profiles of 
the two mouse types unquestionably promoted the idea that the presence of T cells was not 
an absolute prerequisite for the development of psoriasis. The JunB/c-Jun knockout mouse 
is  one  of  the  most  complete  animal  models  for  psoriasis,  spontaneously  developing  a  
psoriasis-like condition with relevant immunological and keratinocyte effects. 
2.3.2 Transgenic K5-Stat3 mouse 
 
Another interesting transgenic mouse model for psoriasis is transgenic mouse with 
constitutively active Stat3 overexpression. Stat3, a member of the signal transducer and 
activator of transcription aka Stat protein family, participates in cell proliferation, 
apoptosis, cell differentiation and other important biological functions (Yu&Jove 2004). In 
addition, its expression is elevated in psoriasis and in lesional keratinocytes, particularly in 
the nuclei of keratinocytes (Bowcock et al. 2001; Sano et al. 2005a; Sano et al. 2005b). 
Stat3 is activated by many different cytokines, including members of IL-20 subfamily 
cytokines, namely IL-19, IL-20, IL-22 and IL-24, which are all upregulated in psoriatic skin 
(Sa et al. 2007). Of these, IL-22 is produced by Th17 lymphocytes, in contrast to the other 
related cytokines, and its production is induced by IL-23. Overexpression of IL-23 is 
profound in lesional psoriatic skin and Stat3 activation via IL-22 seems to be important in 
the IL-23-induced epidermal acanthosis relevant in the pathogenesis of psoriasis (Zheng et 
al. 2007). 
 
Sano et al. have engineered a Stat3 transgenic mouse, which expresses Stat3 constitutively 
under keratin 5 promoter, targeting expression to the basal layer of epidermis as well as to 
keratinocyte stem cells (Sano et al. 2005a). Stat3 mice were phenotypically normal until the 
age of two weeks. After that their skin became reddened and scaly and development of 
hyperkeratotic lesions was observed in the tail, dorsum and hind feet. The epidermis of the 
affected tails showed marked hyperplasia with elongation of rete ridges, confluent 
parakeratotic scale and loss of the granular layer. In addition, dense dermal infiltrate of 
inflammatory cells, increased number of capillaries and neutrophils were present in the 
epidermis. The keratin expression profile with decreased keratin 1 and upregulated keratin 
6 expression in suprabasal layer reminisced that observed in human psoriatic skin, 
suggesting keratinocyte differentiation alterations similar to those found in human psoriasis. 
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One can conclude that the histological features of Stat3 trangenic mice resembled many of 
the features found in human psoriatic skin. Plaques were also formed after wounding, 
suggesting that constitutive activation of Stat3 increased the sensitivity of the epidermis to 
external stimuli, leading to psoriatic phenotype. This is in concordance with human 
psoriatic skin, as it may also develop a plaque after physical trauma according to Koebner‘s 
phenomenon. Plaque formation after mild wounding was T cell-dependent. When Stat3 
expression was inactivated with topical Stat3-specific oligonucleotide decoy treatment, 
plaques did not develop in response to mild wounding. As Stat3 is a transcription activator, 
it regulates expression levels of various target genes. In the Stat3 transgenic mouse, 
expression of many genes, including Icam1 and Vegf, were upregulated. Upregulated Vefg 
expression was consistent with the thicker and more prominent subcutaneous blood vessels 
in Stat3 mice. Overexpression of Icam-1 promotes the role of T cells in plaque formation of 
Stat3  mice,  as  Icam-1  has  a  role  in  recruiting  T  cells  to  inflammated  skin  (Sano  et  al.  
2005b). Transgenic Stat3 mouse model recapitulates many of the psoriatic features and is 
one of the most complete psoriasis animal models existing today. 
2.3.4 Corneodesmosin knockout mouse 
 
A mouse with a targeted deletion of the corneodesmosin gene (Cdsn) is another highly 
interesting example of genetic engineering targeted at keratinocytes (Matsumoto et al. 
2008). Cdsn is a psoriasis candidate gene located to the PSORS1 locus (Chang et al. 2006). 
Corneodesmosomes are the modified desmosomes of the uppermost layer of epidermis 
participating in corneocyte cohesion and are essential for the proper desquamation of skin. 
Cdsn-deficient mice were born alive and grossly appeared normal, indicating that Cdsn is 
dispensable for embryogenesis. However, Cdsn-deficient mice died of dehydration caused 
by defective skin barrier function a few hours after birth. The mice did not have any other 
major pathological changes. The upper epidermis was missing due to detachment of the 
stratum corneum from the underlying granular layer or within the upper granular layer. 
Also the capillaries beneath the affected epidermis were dilated. In addition the mice had 
impaired hair growth. To study the long-term effects of Cdsn deficiency, skin samples from 
the Cdsn knockout mice were grafted on nude mice. Four weeks after grafting, the samples 
showed a number of psoriasis-like features, including acanthosis, hyperkeratosis, 
parakeratosis, loss of granular layer, severe dermal infiltration of inflammatory cells, 
hyperproliferation, dilation of capillaries and deficient formation of cornified envelope. 
Also structures resembling rete ridges were seen. Interestingly, Stat3 protein was partially 
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translocated to the keratinocyte nuclei of Cdsn-deficient skin grafts, suggesting its 
activation. Activated Stat3 may be relevant in contributing to the psoriatic changes 
observed in grafted Cdsn-deficient tissue. It is noteworthy that psoriasis-like changes 
developed spontaneously (Matsumoto et al. 2008). The mouse model with deficient Cdsn 
gene highlights the fact that Cdsn is relevant for keratinocyte proliferation and 
differentiation. Its relevance as a psoriasis candidate gene is hindered by the observation 
that CDSN mutations in humans cause a hair loss or baldness phenotype without any 
clinical characteristic of psoriasis (Levy-Nissenbaum et al. 2003). 
2.3.5 Transgenic K14-Vegf mouse 
 
Transgenic vascular endothelial growth factor (Vegf) mouse is a good example of a 
psoriasis mouse model with modifications aimed to vascular endothelium. Vegf is an 
important epidermis-derived vessel-specific growth factor. As its expression is upregulated 
in psoriatic lesions it is regarded as an indicator of active psoriasis arthritis (Detmar et al. 
1994; Fink et al. 2007). Upregulation of Vegf expression leads to increased density of 
tortuous cutaneous blood capillaries with a high level of Vegf receptor expression. Based 
on what is known about Vegf and its functions and the role of capillaries in psoriasis, it is 
reasonable to suppose that Vegf is involved in the development of psoriasis.  
 
Vegf transgenic mice were engineered with keratin 14 promoter, directing expression of the 
transgene to the basal layer of the epidermis (Detmar et al. 1998; Xia et al. 2003; Hvid et al. 
2008). Young Vegf mice are healthy and fertile. However, the ear skin of homozygous 
mice  was  redder  than  that  of  control  mice  (Xia  et  al.  2003).  At  the  age  of  three  months,  
Vegf mice began to develop skin lesions characterized by erythematous and scaly skin. 
Interestingly, lesions developed at the sites of highest transgenic Vegf expression. 
Histologically, three-month-old Vegf mice have mild or pre-psoriatic phenotype with 
moderate acanthosis, focal parakeratosis, mild rete ridge formation and increased dermal 
tissue thickness and inflammatory cell infiltration. Also Koebner‘s phenomenon was 
observed in the mice after wounding. After five months of age, transgenic Vegf mice 
developed lesions resembling fully developed human psoriasis plaques with hyperkeratosis 
and parakeratosis and expression of keratin 6 throughout the hyperplastic epidermis. The 
vessels  of  Vegf  mice  in  dermal  papillae  were  enlarged  and  tortuous  and  analogous  to  
vessels in human psoriatic lesions. They also show a similar gene expression profile to that 
observed in human psoriatics with prominent E-selectin, Vcam-1 and Icam-1 expression. 
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The T lymphocyte infiltrate was also similar to that observed in human psoriatics. The 
specific role of the Vegf transgene in the formation of psoriasis-like plaques is supported by 
the fact that the psoriasis phenotype resolved when the function of the transgene was 
blocked.  It  is  still  unclear  how  Vegf  causes  the  psoriasis-like  phenotype,  but  one  
explanation is the elevated levels of vascular adhesion molecules like Icam-1, which have a 
central role in promoting extravasation of inflammatory cells to the skin. Hvid et al. have 
further analyzed K14-Vegf mice with topical TPA treatments and have concluded that 
Th17-driven inflammation is profound in these mice. Th17-driven inflammation is 
supported by the presence of p40, a part of a functional IL-23, essential for maintainance 
and survival of Th17 cells. In addition, other cytokines also detected after TPA treatment, 
including IL-6, IL-22 and IL-17, strongly support a Th17-mediated inflammation. In 
contrast to human psoriatic plaques, despite the presence of IL-12, Vegf mice did not 
promote a Th1 response (Hvid et al. 2008). Altogether, transgenic Vegf mouse represents a 
psoriasis mouse model with striking similarities to human psoriasis and promotes the role 
of vascular capillaries in the development of psoriasis. 
2.3.6 Transgenic K14-interleukin 12 and 23 mice 
 
Inflammatory cells can also be targeted in transgenic mouse models. One example is a 
transgenic mouse in which the p40 gene, a subunit of IL-12 and IL-23, was overexpressed 
in basal epidermal keratinocytes under the K14 promoter. The mice developed cutaneous 
inflammation  but  it  resembled  eczema  and  atopic  dermatitis  more  than  psoriasis,  as  it  
lacked cutaneous CD8 positive T cell infiltrate, which is considered a hallmark of psoriasis 
(Kopp et al. 2001; Kopp et al. 2003; Danilenko 2008).  
 
3. Genetics of psoriasis 
3.1 Inheritance 
 
A familial component in the etiology of psoriasis has already been known for decades. 
Nevertheless, the precise picture of the genetic components behind the disease still remains 
unclear, requiring more research until the final word about the matter is said. The first 
profound study indicating implication of inheritance in the etiology of psoriasis was 
conducted in the Faroe Islands by Lomholt (Lomholt 1963). He investigated almost 11,000 
people, representing one third of the island’s population. The study showed that 91 % of the 
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patients had an affected family member and that the psoriasis incidence was higher among 
first- and second-degree relatives of psoriatics when compared to the entire population. 
Afterwards, studies in other populations have confirmed that genetic background affects the 
pathogenesis of psoriasis (Farber&Nall 1974; Brandrup 1984; Swanbeck et al. 1994). The 
risk for offspring to develop psoriasis is 20 % if one of the parents suffers from the disease, 
and if both of the parents are psoriatics, the risk is 75 %. In addition, when one 
monozygotic twin suffers from psoriasis, the probability for the other twin to develop 
psoriasis varies between 35 to 63 % (Brandrup et al. 1982; Duffy et al. 1993; Sabat et al. 
2007). Monozygotic twins also share a similar clinical disease course whereas in dizygotic 
twins disease patterns vary. In dizygotic twins the concordance is considerably lower, 
varying between 12 to 15%. Based on the twin studies, the total heritability is estimated to 
be 91% (Barker 2001). The fact that concordance between monozygotic twins is less than 
100 % shows that in addition to genetic background, environmental factors also affect the 
onset of psoriasis. Even though genetic predisposition seems to have an important role in 
the susceptibility to develop psoriasis, the inheritance pattern that psoriasis follows suggests 
that psoriasis is a complex disease and its inheritance is multifactorial (Henseler 1997; 
Sabat et al. 2007). 
 
A considerable amount of genetic research has been done through the years in order to 
identify the genes behind psoriasis. Genetic susceptibility studies usually involve an 
attempt to identify the allelic variants significantly associated with the increased risk of the 
disease under study (Valdimarsson 2007). There have been different kinds of genome wide 
approaches used for the purpose and linkage analysis was the first. It relies on the fact that 
marker alleles near a disease gene are co-inherited with the disease gene within a family 
unless a recombination has occurred. Inheritance of a marker allele is monitored in a family 
that has both affected and unaffected members. As the knowledge of the variation in the 
human genome has increased, association analysis has become widely used. In association 
analysis, the frequencies of alleles with single nucleotide polymorphisms (SNPs) between 
the cases and controls are analyzed. Lately large genome-wide association studies (GWAS) 
have become more popular. In GWAS, frequencies of hundreds of thousands of SNPs are 
compared between cases and controls (Duffin&Krueger 2008). Genome-wide analyses of 
psoriasis susceptibility genes have indicated the presence of numerous different 
susceptibility loci.  
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3.2 The PSORS1 locus 
 
The psoriasis susceptibility 1 locus (PSORS1) is the major locus for psoriasis. It is located 
in the MHC region on chromosome 6p21.3 and the association of psoriasis with the specific 
HLA-C gene form (HLA-Cw6) in the MHC region has been known for more than 25 years 
(Tiilikainen et al. 1980). PSORS1 accounts for 30-50% of the genetic predisposition to 
psoriasis (Trembath et al. 1997) and the association has been consolidated in different 
populations, all indicating significant linkage (Nair et al. 1997; Burden et al. 1998; 
Samuelsson et al. 1999; Lee et al. 2000; Veal et al. 2001; International Psoriasis Genetics 
Consortium 2003). Interestingly, the strength of the genetic linkage and association with 
PSORS1 and  psoriasis  is  among the  strongest  for  any  complex  disease  (Kere  2005).  The  
PSORS1 risk locus increases the possibility to develop psoriasis by 2.5-fold and it shows a 
dominant-like inheritance pattern (Asumalahti et al. 2002). 
 
The exact genomic localization of the PSORS1 effector gene is still unclear 
(Bowcock&Barker 2003). It was considered most likely that the PSORS1 gene locates in a 
region of about 200 kb telomeric from HLA-C (Oka et al. 1999; Nair et al. 2000). The area 
includes eight genes, namely HLA-C, POU5FI (OTF3), TCF19, CCHCR1 (HCR, Pg8), 










Figure 4. Genes in the PSORS1 locus on chromosome 6p21. 
 
Genes located in the PSORS1 region, especially HLA-C, CCHCR1 and CDSN are in strong 
linkage disequilibrium, which has prominently hindered the genetic studies of PSORS1. 
Even though the original association found was between psoriasis and HLA-C, it has been 
proposed that HLA-C would be in strong linkage disequilibrium with the actual PSORS1 
gene (Jenisch et al. 1998). Despite the well-characterized association of HLA-Cw6 and 
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psoriasis and the significant amount of research done to identify the mechanism for the 
gene to promote pathogenesis of psoriasis, the mechanisms still remain unclear (Bos&De 
Rie 1999). In addition, the high-risk haplotype bearing HLA-Cw6 may associate with 
psoriasis more strongly than HLA-Cw6 alone. Neither does the biological role of HLA-C 
promote it as a PSORS1 effector gene: the HLA-C participates in antigen presentation for 
natural killer and CD8 positive T cells, whereas the primary pathogenic cell population in 
psoriatic skin is CD4 positive T cell (Barker 2001). HLA-C is expressed in skin, 
predominantly suprabasally in the epidermis with a membrane-like expression pattern, and 
its expression level is elevated in psoriatic plaques (Carlen et al. 2007). In addition to HLA-
C, other PSORS1 genes have also been considered as susceptibility genes for psoriasis. 
According to recent investigations, the most strongly associating SNP in the PSORS1 
region was located 34.7 kb upstream from the transcriptional start site of HLA-C (Liu et al. 
2008). Thus, despite the shortcomings and lack of a functional understanding for HLA-C in 
the pathogenesis of psoriasis, many consider it as the strongest PSORS1 candidate gene. 
 
Corneodesmosin  (CDSN,  S  gene)  is  one  of  the  candidates  for  PSORS1  gene.  CDSN  is  
expressed in terminally differentiated granular keratinocytes and CDSC protein localizes to 
the modified desmosomes ensuring the intercellular cohesion of keratinocytes (Simon et al. 
2001; Jonca et al. 2002). Corneodesmosomes are modified desmosomes in the uppermost 
layer of the epidermis (Matsumoto et al. 2008). Presence of CDSN is essential for normal 
desquamation (Chang et al. 2006). CDSN has many psoriasis-associated genotypes 
including CDNS*971T, CDNS*TTC and CDSN*5, but the evidence supporting CDSN as 
the effector gene of PSORS1 has shown differences between populations (Asumalahti et al. 
2000; Ameen et al. 2005; Martinez-Borra et al. 2005; Chang et al. 2006). Variations 
between different populations do not support CDSN as the PSORS1 gene.  
 
Corneodesmosin expression is enhanced in psoriatic plaques as compared to healthy or 
non-lesional psoriatic skin (Allen et al. 2001; Simon et al. 2008). The psoriasis-associated 
CDSN*971T form has increased mRNA stability (Capon et al. 2004a). Interestingly, 
proteolysis of CDSN, a process prerequisite for desquamation, is altered in psoriasis but the 
defects are independent from the CDSN genotype (Simon et al. 2008). Recently, a mouse 
model with a targeted deletion in Cdsn gene was engineered by Matsumoto et al. in order to 
study  the  role  of  CDSN in  mouse  skin  (Matsumoto  et  al.  2008)  (see  section  “Genetically  
engineered mouse models). Interestingly, longer-term effects of CDSN deficiency 
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resembled psoriasis in numerous characteristics. The functional properties of CDSN are 
highly relevant for psoriasis, but the genetics do not support it solely as the PSORS1 gene. 
Also, mutations in CDSN have been described in humans in the context of hair loss or 
baldness, and the patients have no signs whatsoever of a psoriatic phenotype (Levy-
Nissenbaum et al. 2003). In addition, according to the latest genome-wide association 
analysis CDSN does not localize at the region of the strongest PSORS1 association (Zhang 
et al. 2009).  
 
There are also other genes located in the PSORS1 locus but their importance as the effector 
gene for PSORS1 appears even less convincing. POU5F1 codes for transcription factor 
Oct-3/4 that has an essential role in the formation of a pluripotent founder cell population in 
the mammalian embryo and the amount of Oct-3/4 is highly relevant as different levels 
induce divergent developmental programs. POU5F1 has been suggested to be a highly 
important regulator of pluripotency (Niwa et al. 2000). As POU5F1 has a focal role in 
embryogenesis, including cardiac development (Zeineddine et al. 2006), and its expression 
levels have profound effects on embryogenesis, it is unlikely that defects in POU5F1 could 
cause as mild of a phenotype as psoriasis. Transcription factor 19s (TCF19, ac. SC1) 
expression is regulated according to cell cycle and is classified as a late growth-regulated 
gene. TCF19 has been proposed to code trans-activating factor, having a role in the 
transcription of genes required for the late stages of cell cycle progression (Ku et al. 1991), 
but more evidence is needed to be able to ascertain its exact role. PSORS1C1 and 
PSORS1C2 (Psoriasis susceptibility 1 candidate gene 1 and 2, also known as SEEK1 and 
SPR1) are both expressed in healthy and psoriatic skin and have psoriasis-associated SNPs. 
Association of SPR1 gene with psoriasis is dependent on HLA-CW6. In SEEK1, two SNPs 
associate with psoriasis independently from HLA-CW6 but the SNPs do not cause an 
amino acid change and the exon where the SNPs locate is not translated to protein (Holm et 
al. 2003). Several lines of investigation have suggested that SEEK1 should not qualify as 
the effector gene of PSORS1 (Rahman et al. 2005; Chang et al. 2006). STG gene is 
expressed in tonsils and healthy skin but not in keratinocytes or psoriatic skin. STG is a 
polymorphic  gene  but  the  polymorphisms  do  not  associate  with  psoriasis  (Sanchez  et  al.  
2004). 
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3.3 Other psoriasis loci 
 
As PSORS1 accounts for 30-50% of the familial psoriasis cases and its penetrance is 10-
15%, existence of other psoriasis susceptibility loci is probable (Bowcock&Krueger 2005). 
It is likely that there is not only one gene responsible for the pathogenesis of psoriasis, but 
rather is more likely to be caused by the cooperation of many genes. Presence of at least 
nine psoriasis susceptibility loci has been proposed based on genome-wide linkage studies 




PSORS2 locus is located on chromosome 17q25 and its association to psoriasis has been 
confirmed in different Caucasian populations (Tomfohrde et al. 1994; Nair et al. 1997; 
Enlund et al. 1999; Samuelsson et al. 1999). The locus includes four genes, namely 
SLC9A3R1 (Solute carrier family 9), EBP50, NAT9 (N-acetyltransferase 9) and RAPTOR 
(Tomfohrde et al. 1994; Speckman et al. 2003; Bowcock&Krueger 2005). Helms et al. have 
shown that PSORS2 has two separate association peaks, one of which is located to the 
proximity of SLC9A3R1 and NAT9 (Helms et al. 2005). SLC9A3R1 is a phosphoprotein 
proposed to have a diverse role in the epithelial membrane biology and immune synapse 
formation in T cells. SLC9A3R1 expression is most prominent in the uppermost spinous 
cell layer of both psoriatic and normal skin and also in inactive T cells. SNPs found in the 
close proximity to SLC9A3R1 and NAT9 cause the loss of transcription factor RUNX1 
binding. Interestingly, RUNX1 is needed for normal hematopoiesis, including development 
of thymic T cells,  and activates production of IL2 and IFN-  in DC4+ T cells (Ono et  al.  
2007). A common haplotype carrying SLC9A3R1 and NAT9 has been shown to associate 
with psoriasis in one US patient population but the risk associated with the haplotype is 
low, with the odds ratio lower than 1.2. It has been argued that the genetic background 
behind autoimmune disease includes a combination of relatively common haplotypes or 
alleles causing the disease (Bowcock&Krueger 2005). PSORS2 also includes another 
susceptibility locus that encodes RAPTOR gene (regulatory associated protein of MTOR) 
(Hara et al. 2002; Capon et al. 2004b; Helms et al. 2005). MTOR (mammalian target of 
rapamycin) is a protein kinase that regulates cell growth and proliferation in response to 
environmental  stimuli  and its  activation is proposed to be regulated by RAPTOR (Kim et 
al. 2002). RAPTOR is expressed in a variety of tissues including lesional and non-lesional 
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psoriatic skin. Variations of RAPTOR predisposing to psoriasis locate to the non-coding 
region,  suggesting  a  possible  regulatory  role.  However,  the  relevance  of  RAPTOR  as  a  




Matthews et al. found linkage association for psoriasis to chromosome 4q in English and 
Irish families (Matthews et al. 1996). The PSORS3 locus contains a candidate gene called 
interferon  regulatory  factor  2  (IRF2),  whose  function  is  relevant  for  the  pathogenesis  of  
psoriasis (Foerster et al. 2004). However the association has not shown replication in other 
populations ( Nair et al. 1997; Enlund et al. 1999; Zhang et al. 2002). 
3.3.3 PSORS4 
 
PSORS4 has been located to chromosome 1q21 in numerous populations 
(Bhalerao&Bowcock 1998; Capon et al. 1999; Chen et al. 2009). Interestingly, PSORS4 
includes several genes participating in epidermal differentiation as it is located in the 
epidermal differentiation complex (EDC). EDC is a group of 70 genes expressed during 
terminal keratinocyte differentiation, including genes encoding S100 proteins, small 
proline-rich proteins (SPRRs) and late envelope proteins (Bowcock&Krueger 2005). 
Numbers of genes have been suggested as PSORS4 candidate genes, including S100A8, 
S100A9 and loricrin which all show allele-specific differences in expression profiles 
(Semprini et al. 2002; Giardina et al. 2004). Also peptidoglycan recognition proteins 
(PGLYRP) and involucrin genes have been suggested to associate with psoriasis (Chen et 
al. 2009; Kainu et al. 2009). Recently  one  PSORS4  gene,  LCE3C,  a  member  of  the  late  
cornified envelope gene cluster, was shown to have variability in copy number in psoriatics 
as they were shown to have a higher percent of reduced number of the gene than healthy 
individuals (de Cid et al. 2009). 
3.3.4 Other psoriasis loci 
 
The linkage association of psoriasis to PSORS5 locus was originally detected in a Swedish 
population (Enlund et al. 1999). PSORS5 is located on chromosome 3q21 and includes the 
candidate gene SLC12A8, a member of solute carrier family 12 (Hewett et al. 2002; 
Huffmeier et al. 2005). There are also other interesting genes located in PSORS5. One 
example is Cystatin A, a gene coding for skin barrier cysteine protein inhibitor whose 
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expression is upregulated in psoriatic plaques. However, its association to psoriasis has 
been controversial and the association is dependent on PSORS1 genotype (Samuelsson et 
al. 2004; Vasilopoulos et al. 2008). 
 
Genome-wide linkage scan with German families indicated the presence of PSORS6 locus 
on chromosome 19p13 (Lee et al. 2000). The JunB gene is located in PSORS6. JunB 
expression is downregulated in psoriatic lesional keratinocytes and it has been shown to be 
relevant for the pathogenesis of psoriasis as the mouse model deficient in JunB/c-Jun 
develops a psoriasis-like phenotype (Zenz et al. 2005) (see section “Genetically engineered 
mouse models”). 
 
Another psoriasis susceptibility locus, PSORS7 locus is located on chromosome 1p. The 
EPS15 gene producing intracellular substrate of the EGF receptor and overexpressed in 
psoriatic  epidermis  is  located  in  the  area  (Veal  et  al.  2001).  Otherwise  the  locus  remains  
poorly characterized. 
 
PSORS8 locus in chromosome 16q has also been identified (Nair et al. 1997; Karason et al. 
2003). Interestingly, Crohn’s disease variant gene NOD2 is also located in 16q. However, 
studies have eliminated the possible role of NOD2s as a psoriasis candidate gene and more 
data is needed to clarify the role of PSORS8 in the genetics of psoriasis (Young et al. 
2003). 
 
The PSORS9 locus on chromosome 4q31-4q32 was identified in a Chinese Han population 
(Yan et al. 2007; Zhang et al. 2007). The IL-15 gene is located in the area and it has been 
pointed out as a susceptibility gene, as a SNP in 3’ UTR of the gene associates strongly to 
psoriasis and also has effects on the expression pattern of the gene (Zhang et al. 2007). 
 
In  addition  to  the  PSORS1-9  loci,  other  loci  have  also  been  suggested  to  exist.  A  recent  
addition to the list of loci associated with psoriasis is a novel psoriasis locus on 2p22.3 - 
2p11.2, identified in the Chinese Han population (Sun et al. 2008). Genome-wide 
association analysis has proposed a novel psoriasis locus to chromosome 4q27, an area 
harboring genes for interleukin 2 and interleukin 21 relevant in the pathogenesis of many 
autoimmune  diseases  (Liu  et  al.  2008).  The  variety  of  psoriasis  loci  indicates  the  
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multiplicity of genes affecting the disease and also suggests that there may be true 
differences between different populations. 
 
4. The psoriasis susceptibility gene CCHCR1 
 
The Coiled-Coil -Helical Rod Protein 1 (CCHCR1, former HCR and Pg8) was originally 
predicted from genomic sequence by Guillaudeux et al. (Guillaudeux et al. 1998), after 
which the gene finding was verified and the gene renamed by Oka (Oka et al. 1999). 
Asumalahti et al. further characterized it as a novel psoriasis susceptibility candidate gene 
(Asumalahti et al. 2000). CCHCR1 is located in PSORS1 region between HLA-C and 
corneodesmosin (Figure 4) and is in strong linkage disequilibrium with HLA-C both in 
psoriatics and healthy persons. CCHCR1 gene is highly polymorphic with at least 12 
coding variants in addition to non-coding SNPs, both in exon and intron areas, and the gene 
codes a protein of 782 amino acids. The secondary structure is predicted to include -
helical coils and its amino acid sequence shows only little homology with other known 
proteins. Predictions suggest CCHCR1 to be a nuclear protein with a leucine zipper motif 
(Asumalahti et al. 2000). Four of the coding SNPs form the psoriasis susceptibility allele 
CCHCR1*WWCC (SNPs correspond to nucleotides 307, 325, 1723 and 2327), where two 




Figure 5. Schematic structure of CCHCR1 protein. Rectangles represent localizations of predicted 
helical structures, which are flanked by intervening non-coiled structures. Approximate localization 
of CCHCR1*WWCC SNPs and the numbers of amino acids (aa) of different domains are presented. 
 
The CCHCR1*WWCC psoriasis-associated gene form with an odds ratio of 2.5 (1.9-3.3) is 
found  on  35  %  of  psoriatic  chromosomes  and  18  %  of  control  chromosomes,  suggesting  
that CCHCR1*WWCC has a role in the pathogenesis of psoriasis. Relevance of CCHCR1 
as a PSORS1 candidate gene has been argued (Chia et al. 2001; O'Brien et al. 2001), but its 
association with psoriasis has been successfully replicated in Jewish, Chinese and Taiwan 
Chinese psoriatics, suggesting its relevance in different populations (Chang et al. 2004; 
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Chang et al. 2005; Martinez-Borra et al. 2005). CCHCR1*WWCC variant may have an 
altered secondary structure as the first two amino acids of the genotype predicted affect the 
secondary structure by decreasing the probability of helical coiled-coil structure 
(Asumalahti et al. 2002).  
 
CCHCR1 is expressed by a variety of tissues, with the most abundant expression found in 
heart, liver, skeletal muscle, kidney, testis and pancreas and weaker expression in lung, 
spleen, thymus, prostate, ovary, small intestine, colon, peripheral blood leukocytes, brain 
and placenta (Asumalahti et al. 2000; Sugawara et al. 2003). In healthy and non-lesional 
psoriatic skin, CCHCR1 protein expression is confined to basal keratinocytes and the 
expression pattern is uniform. In psoriatic lesions, CCHCR1 expression is more abundant 
and the expression is enhanced within nuclei and cytoplasm of basal keratinocytes and also 
suprabasally above dermal papillae. Rete ridges are mostly negative for CCHCR1 
expression. Interestingly, CCHCR1 expression shows an inverse expression pattern 
compared to the proliferation marker Ki-67, suggesting a less prominent CCHCR1 
expression at the sites of active proliferation (Asumalahti et al. 2000; Asumalahti et al. 
2002; Suomela et al. 2003). CCHCR1 is also expressed in some epidermally originating 
cancers, and interestingly, it shows an inverse expression pattern compared to the 
hyperproliferation marker Ki-67 also in cancers (Suomela et al. 2003). In cultured lesional 
keratinocytes, CCHCR1 expression is enhanced and nuclear localization has also been 
observed. Gene regulation of CCHCR1 has been studied by treating keratinocytes with 
different psoriasis-related cytokines. However, only INF-  affects CCHCR1 expression by 
downregulating it (Suomela et al. 2003). 
 
In addition to humans, CCHCR1 gene is also found in other animal species, including Pan 
troglody (common chimpanzee), Pongo abelii (Sumatran orangutan), Mus musculus (house 
mouse), Bos taurus (European cattle) and Xenopus tropicalis (diploid frog). The coding 
sequence homologies of CCHCR1 between different species vary between 70% and 87 %. 
The highest homology, 99%, is between chimpanzee and human. Xenopus tropicalis is an 
exception as it does not show any significant similarity to human CCHCR1. The homology 
of the human and mouse CCHCR1 coding regions as well as amino acid sequence is 72% 
and interestingly the three first SNPs of CCHCR1*WWCC allele are located to the 
homologous areas. In the genomic sequence, the homology between human and mouse 
CCHCR1 gene is 39 %.  
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The functional aspects of CCHCR1 have remained poorly understood. CCHCR1 is not 
expressed by the areas of active proliferation, which suggests a role in keratinocyte 
proliferation. The dual localization in cytoplasm and nucleus suggests a possibility for a 
functional role in both cell compartments. In addition, CCHCR1 participates in 
steroidogenesis as Sugawara et al. have shown that CCHCR1 enhance steroidogenesis by 
interacting with the steroidogenic acute regulatory protein (StAR) (Sugawara et al. 2003). 
StAR protein plays a key role in the transportation of cholesterol from the outer 
mithocondrial membrane to the inner membrane, where the first step of steroid hormone 
synthesis occurs as the cytochrome P450 side chain cleavage enzyme (P450scc) facilitates 
conversion  of  cholesterol  to  pregnenolone.  StAR  expression  is  confined  to  steroid-
producing tissues, but whether it is expressed in skin was unknown, although 
steroidogenesis also occurs in skin (Thiboutot et al. 2003; Zouboulis&Degitz 2004; Stocco 
et al. 2005). Steroid hormones have profound effects in skin, as they are needed for cell 
proliferation, epidermal barrier homeostasis, differentiation and modulation of immune 
response, all processes relevant for the pathogenesis of psoriasis (Zouboulis&Degitz 2004; 
Bikle et al. 2005). Even though something about the function of CCHCR1 is already 
known, more research is needed to find out its detailed function and relevance for the 
pathogenesis of psoriasis. 
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The overall goal of the study was to investigate the function of CCHCR1 and its relevance 
for the pathobiology of psoriasis by mouse models and functional studies with cultured 




I To establish and characterize transgenic CCHCR1 mice expressing either the 
non-risk or risk form of CCHCR1 and to study the role of CCHCR1 in 




II To investigate the role of CCHCR1 in the steroidogenesis of skin and its 
interaction with the StAR protein. 
 
 
III To study CCHCR1 expression and its regulation in cultured keratinocytes in 




MATERIAL AND METHODS 
 
1. Experiments with transgenic CCHCR1 mice 
1.1 Transgenic constructs and production of transgenic mice (I) 
 
Two types of constructs were engineered in order to produce transgenic CCHCR1 mice, 
producing either the normal human allele of CCHCR1 or the psoriasis-associated 
CCHCR1*WWCC risk allele under the control of the K14 promoter. Cloning of the normal 
human CCHCR1 allele was done by Asumalahti et al. (Asumalahti et al. 2000; Asumalahti 
et al. 2002). Risk allele cDNA was obtained by reverse transcriptase PCR (RT-PCR) using 
RNA isolated from a skin biopsy of a psoriasis patient with a CCHCR1*WWCC risk allele. 
The primers used in RT-PCR were the following: forward primer containing a BamHI site 
5’-CGCGGATCCCTTTCAACTCTGCCAAGA-3’ and reverse primer 5’-CCAC 
CCACTTCTCCAGGAT-3’. Normal and risk form cDNAs of CCHCR1 were first cloned 
into the pCMV5 vector, from which they were transferred to the K14 expression vector 
PG3Z-K14 cassette (Gat et al. 1998). Before transfer the SphI and HindIII restriction sites 
at  3’ side of the polyA in the pG3ZK14 were used to introduce additional SmaI and SacI 
sites, in order to allow the recovery of linear K14-CCHCR1 fragment for pronuclear 
injection. For that purpose, a restriction cassette of 37 bp containing sites for SphI, SmaI, 
SacI and HindIII was synthesized using the oligonucleotides 5’-
GCAGCATGCTGCCCGGGGAGAGCTCCTCAAGCTTCTT-3’ and 3’-CGTCGTAC 
GACGGGCCCCTCTCGAGGAGTTCGAAGAA-5’. 
 
Using BamHI sites, the CCHCR1 cDNAs, including the entire coding regions flanked by 
52 bp 5’ and 42 bp 3’ untranslated sequences, were transferred from pCMV5 vector into 
pG3ZK14. Restriction mapping and direct sequencing were used to validate the orientation 
of CCHCR1 inserts and fidelity of the sequence. The linearized transgenic fragments 
containing the K14 promoter, b-globin intron, human CCHCR1 cDNAs and polyA were 
released from the vector with SacI. Fragments were purified with agarose gel 
electrophoresis combined with Gel Extraction Kit (Qiagen). The fragments were eluted 
with ultrapure buffer containing 10 mM Tris (pH 7.5) and 0.2 mM EDTA. The transgenes 
were microinjected into the pronuclei of fertilized oocytes of FVB/N mice (Jackson 
Laboratories, Bar Harbor, USA). Altogether, 81 mice with non-risk allele constructs and 75 
with risk allele constructs were obtained for further screening. K14-CCHCR1 founder mice 
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were crossed with the FVB/N mice in order to establish a co-isogenic transgenic line. 
Tissue specimens for RNA, protein and histological analyses were collected at different 
ages (1, 2, 4, 6 and 12 months). All animal studies were approved by the regional 
committee for animal experiments at the University of Helsinki (license number STU 27 
A/2002). 
1.2 Screening of transgenic mice (I) 
 
Potential founders and littermates were screened for transgene integration by PCR. 
Genomic DNAs were isolated from tails, digested in 40 mM Tris-HCl, pH 8.0, 20 mM 
EDTA, 200 mM NaCl, 0.5 % SDS, 0.5 % -mercaptoethanol and 20 mg/ml proteinase K at 
60 °C overnight. After digestion, the DNAs were precipitated with isopropanol, washed 
with ethanol and dissolved in water. Samples were analyzed by PCR using a forward 
primer annealing to K14 sequence (5’-ACATCCTGGTCATCATCCTGCC-3’) and a 
reverse primer annealing to CCHCR1 sequence (5’-CTAGCCGCCTCTCTGAGACATC -
3’). The PCR results of founder animals were verified with Southern blotting by using a 
K14 promoter specific fragment of 795 bp as a probe. The K14-fragment was generated by 
PCR using a forward primer 5’-AAGCCTGGGCAATAACAATG-3’ and a reverse primer 
5’-GAAAGCCCAAAACACTCCAA-3’. Southern blotting was performed according to 
standard protocols and blots were visualized by autoradiography. 
1.3 Wounding experiments (III) 
 
Age matched adult mice homozygous for the risk or non-risk CCHCR1 alleles were used 
for the experiments. Heterozygote mice from non-risk lines 12 and 34 or risk lines 106 
and 132 were crossed to produce homozygote mice used in the experiments. Mice were 
anesthetized with ketamine hydrochloride (50 mg/kg sc) and xylazine hydrochloride (10 
mg/kg sc). Two to three circular full-thickness wounds 5 mm in diameter were made using 
a punch biopsy device on both sides of the previously shaved backs of the anesthetized 
mice.  Mice  were  sacrificed  after  1,  4,  11,  and  30  days  post  wounding  and  wound areas  
were measured. At each time point, four animals from each mouse group were used for 
analyses. After harvesting, tissues were fixed in neutral formalin, dehydrated and 
embedded in paraffin. Hematoxylin and eosin (H&E)-stained sections were photographed 
and analyzed with Olympus BX41 microscope and computer using the Olympus DP-soft 
version 3.2 image program. Eight wounds per genotype were used for the analyses. Re-
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epithelialization was estimated on skin sections by measuring the distance between the 
original wound site (the edge of the muscular layer) and the leading edge of the 
epithelium.  
1.4 TPA treatment (III) 
 
Shaved backs of the age matched, three-month-old mice were treated with 10 g 12-O-
tetradecanoylphorbol-13acetate (TPA, Sigma) in 100 l acetone. The solution was applied 
over an area of approximately 2x2 cm. At each time point, four animals from each group 
were used and the animals were sacrificed at defined time points (24, 48 or 72 h) after 
which the skin samples were processed for histological analysis. Two skin cross-section 
samples from each mouse were analyzed as the epidermal thickness from the bottom of the 
stratum corneum to the basement membrane of the interfollicular epidermis was measured. 
Four measurements on four to seven fields per mouse were made using Olympus BX41 
microscope and computer using the Olympus DP-soft version 3.2 image program. 
1.5 In vivo cell proliferation assay with untreated mice (III) 
 
Proliferation of epithelial cells was measured by intraperitoneal injection of BrdU (Roche) 
50 mg/kg body weight. Four mice were used for each time point in each group and mice 
were sacrificed 2 or 6 hours after injection. BrdU incorporation was detected by 
immunohistochemical staining with mouse anti-BrdU monoclonal antibody (Dako). The 
number of BrdU positive cells in relation to the total number of epidermal keratinocytes 
was determined from two to three sections per animal and on five to seven fields of each 
section.  
 
2. Experiments with transgenic primary mouse keratinocytes 
2.1 Isolation and culture of primary mouse keratinocytes (II, III) 
 
Keratinocytes from 0- to 3-day-old transgenic CCHCR1 mice (I) or from wild-type 
animals were isolated. Mice were sacrificed and the skin was removed and incubated in 
0.25 % dispase in EBSS overnight at 4 ºC. On the following day the epidermis was 
separated from the dermis, washed, and incubated in 0.25% trypsin solution for 15 min in 
37 ºC. Epidermal pieces were suspended by pipetting in keratinocyte growth medium 
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(KGM-2 media supplemented with growth factors, Clonetics, Cambrex Bio Science 
Walkersville, Inc., MD, USA) supplemented with 8 % decalcified FCS and penicillin-
streptomycin. After suspension, the cells were centrifuged (200 x g, 10 min). The pelleted 
keratinocytes were resuspended in KGM-2 medium supplemented with 2 % decalcified 
FCS and penicillin-streptomycin and seeded in plates for further cultivation. On the 
following day the media were changed to KGM-2 without serum. All animal studies were 
approved by the regional committee for animal experiments at the University of Helsinki 
(license number STU402A). 
2.2 Proliferation assay of primary mouse keratinocytes (III) 
 
For the cell proliferation assays, isolated primary mouse keratinocytes (see previous 
section) were resuspended in KGM-2 medium supplemented with 2% decalcified FCS and 
penicillin-streptomycin, counted and 5,000 or 10,000 cells were seeded in 96-well plates. 
Cells were cultured in the presence or absence of EGF (15 ng/ml, Sigma) for 2-3 days, after 
which cells were labeled for 2, 4, 8 or 24 h with 10 M BrdU (Roche). Colorimetric ELISA 
System (Roche Diagnostics, Germany) was used to determine the amount of incorporated 
BrDU and the assays were done according to the manufacturer’s instructions. Absorbance 
(450  nm)  values  were  plotted  as  a  function  of  time,  and  proliferation  rates  ( A450 nm/ h) 
were estimated from the slope of the line. 
2.3 In vitro cell migration assay (III) 
 
For the cell migration assays, keratinocytes from newborn mice were isolated (see section 
“Isolation and culture of primary mouse keratinocytes”), counted and plated in 6-well 
plates or in Transwell inserts (8 m membrane, Costar) coated with 10 g/cm2 rat 
collagen type I (Sigma). Cells in 6-well plates were cultured in the presence or absence of 
15 ng/ml EGF (Sigma) 2-3 days and used for the experiments when they were 70-90% 
confluent. To examine cell motility, a cell-free area was introduced by scraping the cell 
layer with a pipette tip and after 24 and 48 h of migration, the cell-free area was evaluated 
(Matthay et al. 1993; Cha et al. 1996). Photographs were taken with a phase contrast 
microscope. Cells in Transwell chambers were let to migrate 24 or 48 h after which 
migrated cells were fixed with methanol. Hematoxylin-stained inserts were mounted and 
migrated cells were counted by microscope. The rate of re-epithelialization was studied 
42 
from mouse skin explants with fluorescence imaging technique (Lu&Rollman 2004; 
Mirastschijski et al. 2004).   
 
3. Expression studies of CCHCR1 
3.1 Cell cultures for regulation studies (II)  
 
HaCaT keratinocytes were cultured and treated with different hormones and chemicals to 
study regulation of CCHCR1. Cells were seeded on 6-well plates and cultured in DMEM 
(Gibco, High glucose) with 10 % FCS and before experiments cells were cultured without 
serum overnight. Subconfluent or confluent cells were treated with estradiol (10-9 – 10-6 
M, Sigma), insulin (10-7 - 10-5 M, Sigma), forskolin (10-6 -10-4 M, Sigma), cyclosporine (1-
100 ug/ml, Sigma) progesterone (10-9-10-5 M, Sigma), 5 -dihydrotestosterone (10-8 – 10-6 
M Sigma), Cyclosporin A (5-100 µg/ml, Sigma) and 3,3`,5-triiodo-L-thyronine sodium 
salt (Sigma 10-9 - 10-6M) for 24 or 48 hours. Experiments included triplicate samples from 
each treatment group and experiments were repeated three times. Mock treated cells were 
used as controls. Also transient cholesterol depletion was carried out by incubating serum-
starved cells with 7.5 mM methyl- -cyclodextrin (M CD) (Sigma) for 1 h followed by 17 
h incubation in serum-free culture medium. Chronic depletion of cellular cholesterol was 
done with 1 hour M CD treatment, followed by inhibition of cholesterol biosynthesis with 
10 M lovastatin (Sigma) treatment for 17 hours (Jans et al. 2004). In addition cultured 
HaCat  cells  were  also  treated  with  EGF  (10  ng  per  ml)  for  24h  prior  to  use  in  western  
analyses.  
3.2 mRNA expression analyses  
 
3.2.1 Isolation of RNA for RT and quantitative real time PCR (I, II)  
 
Total RNAs were isolated from cultured keratinocytes or skin samples with RNAeasy 
Total RNA Isolation Kit (Qiagen, Chatswort, California) according to manufacturer‘s 
protocol including DNase I treatment. RNA was reverse-transcribed to cDNA with 
TaqMan Reverse Transcription Reagents (Applied Biosystems) and used as a template for 
RT-PCR. 
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3.2.2 RT-PCR (II) 
 
StAR expression was studied with RT-PCR from HaCat cells and human primary 
keratinocytes. In the PCR assays, StAR specific primers (5’-
CCTACAGACACATGCGCAAC-3´ and 5’-GCTCCACGAGCTCTTCATAGA-3´) were 
used  with  25  cycles  and  with  an  annealing  temperature  of  55  ºC.  The  PCR  product  was  
used as a template for StAR re-amplification and the re-amplication product was analyzed 
on agarose gel. GAPDH was used as a housekeeping control gene and was amplified with 
the primers 5’-ACGGATTTGGTCGTATTGGG-3’ and 5’-TGATTTTGGAG 
GGATCTCGC-3’. 
3.2.3 Quantitative real-time PCR (I, II) 
 
Real time quantitative PCR assays (TaqMan) were done with the ABI PRISM 7700 
Sequence Detector System (Applied Biosystems). Reaction conditions were programmed 
on a Power Macintosh 7200 directly linked to the sequence detector. PCR amplifications 
were performed according to manufacturer’s recommendations. CCHCR1 gene expression 
was analyzed with human system (Hs00219401_m1, Applied Biosystems) and the vitamin 
D receptor gene was analyzed with human or mouse systems (Hs00172113_m1, 
Mm00437297_m1, Applied Biosystems). In the quantitative real time PCRs done to 
confirm microarray results, the expression of the following murine genes was studied: 
keratin 6a, Mmp9 and S100A10 with pre-designed primer and probe sets (Assay-on-
Demand gene expression product, Applied Biosystems) according to the manufacturer’s 
protocols. GAPDH and ribosomal RNA were used as endogenous control genes in 
quantification (Human GAPDH 20X and Human 18S rRNA 20X and Rodent GAPDH 
Control Reagents, Applied Biosystems).  
3.3 Protein expression analysis 
3.3.1 Immunohistochemical analysis (I, II, III) 
 
Murine epidermal samples for immunohistochemistry were taken from various locations. 
Tissue samples were fixed in 10% formalin solution, embedded in paraffin and sectioned. 
For histological analysis the sections were stained with hematoxylin and eosin. For 
immunodetection of human CCHCR1 protein in transgenic mouse skin tissue, the sections 
were pre-treated with trypsin (10mg/ml) and the localization of CCHCR1 was detected with 
44 
affinity-purified rabbit anti-CCHCR1 IgG (7 µg/ml) (Asumalahti et al. 2002). As a control 
for CCHCR1, stainings with rabbit pre-immune sera (10 mg/ml) or normal rabbit 
immunoglobulin were performed. The following antibodies were used in immunostaining: 
polyclonal antibodies against the proliferation marker Ki67 (Novocastra), mouse 
cytokeratin 5 (Berkeley Antibody Company), filaggrin (Berkeley Antibody Company) and 
T-lymphocyte marker CD3 (Novocastra, United Kingdom), mouse monoclonals for 
cytokeratin 6 (Labvision co, Neomarkers), bromodeoxyuridine (Dako) and -smooth 
muscle actin (Sigma), and rabbit polyclonals for cytokeratin 10 (Covance, PRB159P), Ki67 
(Novocastra, NCL-Ki67p),  laminin 5 (Pyke et al. 1994), von Willebrand factor 
(DakoCytomation) and CCHCR1 (Asumalahti et al. 2002). For the Ki67 and BrDU 
stainings, samples were pre-treated by microwaving in citrate buffer. Immunostainings 
were performed with the avidin-biotin-peroxidase complex technique (Vectastain ABC Kit 
for CCHCR1; Vector laboratories, Inc., Burlingame, CA and StreptABComplex/HRP Duet 
(Mouse/Rabbit) Kit for Ki67; DAKO, A/S Glostrup, Denmark, no. K0492). 
Aminoethylcarbazole or diaminobenzidine were used as a chromogenic substrate. The 
tissues were counterstained with hematoxylin.  Cell apoptosis was visualized using the 
TUNEL labeling system ApoTag Peroxidase In Situ Apoptosis Detection Kit (Chemicon).  
 
Affinity-purified rabbit immunoglobulins anti-CCHCR1 IgG (4 g/ml: Asumalahti et al. 
2002) and anti-StAR (ABR, Affinity Bioreagents PA1-560, 1:200, USA) were used 
according to a standard procedure to detect CCHCR1 and StAR from frozen or paraffin 
human samples including sections of normal skin (n = 3), non-lesional and lesional 
psoriatic skin (n = 6), testes (n = 4), kidney (n = 5), placenta (n = 4), and adrenal gland (n = 
3). 
3.3.2 Staining of transfected cells (II) 
 
COS-1, A431 and HeLa cells were transiently transfected with the pcDNA3.1/V5-His-
StAR, pCMV5-CCHCR1 (non-risk  and  risk  form),  pGFP-CCHCR1 (non-risk form) and 
pHcRedMLN64 constructs using FuGENE 6 reagent (Roche Diagnostics, Germany) 
according to the manufacturer‘s instructions. Cells were fixed with 4% paraformaldehyde-
PBS solution followed by a PBS wash and permeabilization with 0.1% Triton-X100. Cells 
were immunostained with antibodies against CCHCR1 (affinity-purified rabbit 
immunoglobulins 4 g/ml) (Asumalahti et al. 2002), endosomal markers EEA1 (anti-early 
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endosomal autoantigen 1, BD Biosciences, San Jose, CA) and transferrin receptor 
(Zymed) and against the lysosomal marker Lamp1 (Anti-lysosome-associated membrane 
protein from Developmental Studies Hybridoma Bank, University of Iowa). The mouse 
monoclonal antibody against V5-tag (Invitrogen) was used to detect the StAR protein. 
Fluorescently conjugated secondary antibodies (Sigma, Steinheim, Germany) were used 
as secondary antibodies according to the manufacturers’ instructions. Fluorescent Nile 
Red (0.1-0.5 ug/ml Sigma) was used to stain neutral lipid droplets. Filipin staining and 
dextran endocytosis were performed as described before (Höltta-Vuori et al. 2005). To 
visualize the free cholesterol distribution, cells were fixed and incubated with the 
fluorescent sterol-binding antibiotic filipin (0.05% in PBS) for 15 min followed by PBS 
washing. Fluorescent NBD-cholesterol (Molecular Probes, N1148, 22-(N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3beta-ol) was used for detection of 
lipid droplets: transfected cells were labeled from 30 min to 18 h with medium containing 
1-5 g/ml  NBD-cholesterol  at  37  °C  in  a  CO2 incubator.  After  a  PBS  wash,  cells  were  
fixed with 4 % paraformaldehyde prior to use for CCHCR1 immunostaining.  
3.3.3 Western blot analysis (I, II) 
 
Western blot analyses were done to verify CCHCR1 expression in the skin of transgenic 
CCHCR1 mice. After biopsy, mouse skin was frozen in liquid nitrogen and stored at –70 
°C. Tissues were ground with a mortar and pestle in the presence of liquid nitrogen. 
Tissue powders were homogenized into Laemmli buffer with a syringe with needle. 
Samples were boiled for 3 min and centrifuged for 10 min at 4°C. To detect CCHCR1 
expression from HaCat cells, cells were homogenized into Laemmli buffer with a syringe 
with  needle.  The  total  protein  amounts  were  analyzed  with  Bradford‘s  method and  they  
varied between the experiments in the total skin samples, from 10 to 40 mg, and in the cell 
lysates, from 20 to 30 g. Protein samples were analyzed by SDS-PAGE in the presence 
of -mercaptoethanol. Western blot analysis was carried out by using 7.5 % SDS-
polyacryamide gels according to manufacturer‘s recommendation. A rabbit anti-HCR 
serum (Asumalahti et al. 2002) was used to detect CCHCR1 and the signals were detected 
with chemiluminescence (ECL, Amersham Pharmacia). 
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4. Other functional CCHCR1 studies 
4.1 Microarray expression profiling  
4.1.1 Preparation of cRNA for microarray analysis (I) 
 
Total RNA samples from dorsal skin samples of different mouse groups were used for 
microarray hybridization. Two-month-old animals from lines 12, 34, 106 and 132, 
altogether 3 wild-type, 4 non-risk and 4 risk allele animals, were used for the analysis. 
Mouse skin was washed with 70% ethanol and an approximately 2 cm2 piece of the back 
skin was cut for RNA isolation. The samples were rinsed with 70% ethanol and sterile PBS 
and frozen with liquid nitrogen. Total RNAs were isolated using TRIzol (Invitrogen) 
according to the manufacturer’s recommendations. Isolated RNAs were further purified 
with  the  RNAeasy  total  RNA  isolation  kit  (Miniprep-Kit  Qiagen,  Chatsworth,  CA)  
according to the manufacturer’s instructions. To avoid genomic DNA contamination, the 
RNA samples  were  treated  with  DNase  I  (Qiagen).  The  quality  of  RNA was  checked  by  
spectrophotometry (A260/280 ratio), with agarose gel eletrophoresis and the Agilent 
Bioanalyzer (Agilent Technologies Inc.). Double-stranded cDNA was synthesized from 
total  RNA  and  the  cDNA  was  used  as  a  template  in  in vitro transcription to generate 
biotinylated cRNA. Eight g of biotinylated cRNAs were hybridized to each array and 
scanning was performed after biotin/avidin/phycoerythrin amplification. 
4.1.2 Array analysis (I) 
 
U74Av2 murine genome Genechip probe array (Affymetrix Inc, Santa Clara), containing 
probe sets representing approximately 12,000 genes (6,000 well-characterized genes and 
6,000 expressed sequence tags, ESTs), was used. The labeled cRNA was fragmented and 
hybridized to probe arrays according to Affymetrix Expression Analysis technical manual, 
P/N 700218 rev.2. The probe arrays were washed and stained. GeneChip 3.2 software 
(Affymetrix Inc.) was used for image scanning, converting obtained intensities to a 
numerical format and gaining an average difference value for each probe in the array. 
Experimental procedures were done by following the standard protocols provided by 
Affymetrix Inc (Santa Clara, CA). 
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4.1.3 Data analyses (I) 
 
For  construction  of  gene  expression  profiles,  scanned  output  files  were  analyzed  with  the  
Affymetrix  Microarray  Suite  5.0  (Affymetrix  Inc.).  Single  array  analysis  and  comparison  
analysis were used to build databases of gene expression profiles and estimates of gene 
expression changes. Each chip was normalized for all probe sets to a target intensity of 100 
in  order  to  minimize  discrepancies  between  an  experiment  and  baseline  array  due  to  
experimental variations to allow an intermarry comparisons. Comparisons were performed 
between  8  transgenic  mice  and  3  wild-type  mice,  as  well  as  between  the  two  types  of  
transgenic lines. 24 and 16 comparisons were formed from each of the above comparisons 
for further analysis. Differentially expressed genes were defined based on t-test results 
(p 0.001) and fold changes were determined using average values of signal log ratios 
(absolute value 1). Genes were excluded if their expression, as defined by the Affymetrix 
software, was absent in all 11 arrays or if there was no change detected in all comparisons. 
 
To classify genes and to see how well those genes can characterize different mouse lines, 
cluster analysis was performed using GeneSpring 5.1 software (Silicon Genetics, Redwood 
City, CA, USA). Two-dimension hierarchical trees were built based on signal intensity 
values  from  single  array  analysis  of  Microarray  Suite  after  normalization.   Similarity  of  
cluster was measured by standard correlation. Subgroups of genes were used for cluster 
analysis to focus on specific biopathways. Related biological pathways were selected from 
BioCarta (http://www.biocarta.com/index.asp) and altered biological processes were 
determined by changed gene expression profiles by t-test (p 0.001). Information on human 
orthologs was obtained via Affymetrix annotation tools 
(http://www.affymetrix.com/analysis/download_center.affx, March 2003). 
4.2 Steroidogenic pregnenolone assays 
4.2.1 Constructs (II) 
 
Cloning of human CCHCR1 cDNAs corresponding to normal allele (Asumalahti et al. 
2000; Asumalahti et al. 2002) and psoriasis-associated risk allele CCHCR1*WWCC  (See 
section “Transgenic constructs and production of transgenic mice”) have been described 
elsewhere. Both cDNAs were cloned into the pCMV5 vector. StAR cDNA was generated 
by  PCR  using  human  testis  cDNA  (Clontech)  as  a  template.  5’-  
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ACAATGCTGCTAGCGACATTCAAG-3’ primer was used as the forward primer and 
5’-ACACCTGGCTTCAGAGGCAGG-3’  either  with  or  without  the  stop  codon  as  the  
reverse primer. StAR cDNA was cloned into pcDNA3.1/V5-His vector (Invitrogen). The 
F2 construct encoding genes for cytochrome P450scc system was kindly provided by Dr. 
Walter L. Miller (University of California, San Francisco). Wild-type MLN64 was 
described previously (Alpy et al. 2001) and fluorescent fusion construct of MLN64 was 
cloned in pHc-Red1-N1 vector (Clontech). 
4.2.2 Pregnenolone assays (II) 
 
COS-1 cells cultured on 6-well plates were transiently transfected with the F2 construct, 
pcDNA3.1/V5-His-StAR, pCMV5-CCHCR1 (non-risk allele or risk allele) constructs 
using FuGENE 6 reagent (Roche Diagnostics, Germany) according to the manufacturer‘s 
instructions. The native form of StAR in  pcDNA3.1  without  tags  was  also  used  in  some 
assays. After transfection the cells were incubated in 1.5 ml media for 24 h or 48 h, after 
which media samples were collected for pregnenolone quantification. After the sample 
collection  cells  were  cultured  for  an  additional  24  h  with  22R-hydroxycholesterol  (1  
g/ml). In order to compensate for variation in transfection, efficiency assay results were 
normalized with pregnenolone concentrations produced by cultures with 22R-
hydroxycholesterol.  
 
Pregnenolone concentrations of media samples were determined by the LC-MS/MS 
system. Some results were also assayed for comparison with our radioimmunoassay 
method using liquid extraction and Lipidex-5000 microcolumn chromatography prior to 
RIA.  Before  LC-MS/MS  analysis,  30  l of 0.2 M deuterated pregnenolone as internal 
standard (17,21,21,21-D4-pregnenolone, C/D/N Isotopes Inc., Pointe-Claire, Canada) in 
50% (vol/vol) methanol was added to medium samples of 250 l  and  samples  were  
extracted with ether-hexane (90:10). Extracted samples were evaporated to dryness under 
nitrogen and dissolved in 250 l of 50% methanol. Calibrators containing 1-100 nmol/l of 
pregnenolone (Sigma Chemical Co., St Louis, MO) were also prepared in 50% methanol. 
Twenty-five l of sample extracts and calibrators were analyzed with an LC-MS/MS 
system equipped with an API 3000 triple quadrapole mass spectrometer (PE Sciex, Foster 
City, CA). Peripherals included an Agilent series 1100 HPLC system with a binary pump 
(Waldbronn, Germany). Separation was performed using a SunFire C18 column (2.1 x 50 
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mm; Waters, Milford, MA). The mobile phase was a linear gradient consisting of 
methanol and 100 M ammonium acetate in water, at a flow rate of 250 l/min. The 
gradient was: 0 min 50% methanol; 2 min 95% methanol; 3 min 95% methanol; and 3.5-
10 min 50% methanol. The column was directly connected to the electrospray ionization 
probe. Pregnenolone was detected as ammonium adduct in the positive mode with the 
following transitions: m/z 334 to m/z 281 and IS, m/z 338 to m/z 285. Data were acquired 
and processed with the Analyst Software (Ver 1.3; Sciex). The mass calibration and 
resolution adjustments (at 0.7 atomic mass units at full width and half height) on both the 
resolving quadrapoles were optimized using a polypropylene glycol solution with an 
infusion pump. 
 
5. Statistical analysis (I, II, III) 
 
Statistical analyses were made using Microsoft Office Excel. Statistical comparisons 





1. Transgenic CCHCR1 mice 
1.1 Generation of transgenic mice (I) 
 
Transgenic CCHCR1 mouse models were engineered in order to gain more information 
about the function of CCHCR1. As CCHCR1 is expressed in keratinocytes, both in normal 
and psoriatic skin, K14 promoter targeting the transgene expression, predominantly to basal 
epidermal keratinocytes and outer root sheath of hair follicles, was used. We also wanted to 
study  whether  the  function  of  the  psoriasis-associated  risk  allele  CCHCR1*WWCC  is  
different when compared to the common low-risk allele. For that purpose we made two 
constructs where either the wild-type or the psoriasis-associated form of human CCHCR1 
cDNA was placed under the K14 promoter (I, fig 1A). Multiple lines of transgenic mice 
were generated and the incorporation of the transgenes was assured by Southern blots and 
PCR analyses from the genomic murine DNA. Analyses showed successful transgene 
incorporation in 14 normal allele mice out of 81 mice born and in 17 risk allele mice out of 
75 born mice. All transgenic mice were viable and fertile and did not show any obvious 
phenotypic abnormalities (I, fig 1B). Two normal allele and three risk allele mice were used 
as founder animals and bred with the FVB/N strain to generate positive CCHCR1 mice 
lines.  
1.2 Characterization of the transgene CCHCR1 expression (I) 
 
In addition to checking the incorporation of the transgenes in DNA, also their expression 
was studied. Transgene expression on mRNA and protein levels were confirmed by RT-
PCR and western blotting from the skin samples. All the transgenic lines overexpressed 
human CCHCR1 both on mRNA and protein level (I, fig 1C). We also measured transgene 
expression levels with quantitative RT-PCR (TaqMan). To facilitate comparisons between 
the transgenic lines, the acquired expression levels were normalized with the lowest 
expression value (expression of line 132 was set for 1). Normalized expression values for 
non-risk lines 12 and 34 were 3±1 were 8±6 and for risk allele lines 106, 128 and 132 
1.2±1.7, 13±2.8 and 1±0.6, respectively. The variability of the expression levels in one 
mouse line may partially be explained by the sporadic expression of CCHCR1 in epidermis. 
The  copy  doses  of  transgenes  in  different  mouse  lines  were  also  calculated  from  the  
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intensities of the Southern blot bands. The data agreed with the TaqMan-based expression 
values with one exception: line 128 with the highest mRNA expression level seemed to 
have less copies of transgene than lines 12 and 34. 
1.3 Histological evaluation of the transgenic CCHCR1 mice (I) 
 
All transgenic mice were healthy and viable and based on a routine health surveillance mice 
were free from ectoparasite infections. According to PAS stainings, the mice did not have 
fungal colonization either. The skin was morphologically grossly normal and 
indistinguishable between the transgenic and control mice as studied with hematoxylin-
eosin staining (I, Fig. 2A-C). Human CCHCR1 expression was detected from basal 
keratinocytes (I, fig. 2D and E). This is in agreement with the K14 promoter-targeted 
expression. Immunostainings with frozen sections did not reveal additional CCHCR1 
staining when compared to paraffin sections. Wild-type mice were negative with the 
antibody  against  human  CCHCR1  as  expected.  There  were  differences  in  the  
immunostaining intensities between the transgenic lines as well as between the mice 
belonging to the same line. The observation was in agreement with the quantitative RT-
PCR data. CCHCR1 homozygous mice were also morphologically normal. There were no 
obvious differences between the transgenic and wild-type mice stainings with commonly 
used psoriasis markers including proliferation marker Ki67, the differentation marker 
cytokeratin 5 and the T-lymphocyte marker CD3. Taken together, transgenic CCHCR1 
mice appeared healthy and there were no differences or features typical for psoriatic skin 
observed in the mice.   
1.4 Gene expression profiles of microarray analyses (I) 
 
To understand the possible biochemical consequences of CCHCR1 expression in the skin, 
we studied gene expression profiles of the transgenic mice with Affymetrix expression 
analysis. mRNA samples from four risk, four non-risk and three wild-type mice were 
included in the analysis. The transgenic mice were from four different mouse lines and their 
transgene expressions levels did not differ significantly. Differentially expressed genes 
between the different mice groups were identified based on a combination of >2-fold 
expression changes and t-tests (p<0.001). We also considered whether the means of gene 
expression in any two groups were significantly different. In order to verify the Affymetrix 
data, expression of selected genes, namely S100A10, krt-6 and mmp9, were analyzed with 
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quantitative RT-PCR. The results for these selected genes were congruent with the 
Affymetrix  data  (I,  fig.  3D).  Otherwise  expression  results  presented  are  based  on  the  
Affymetrix data. 
1.4.1 Differentially expressed genes between transgenic mice and wild-type mice (I) 
 
When the gene expression of transgenic and wild-type mice were compared, a number of 
significant differences were observed, as 43 genes were at least four-fold upregulated and 
63 genes were at least four-fold downregulated in the transgenic CCHCR1 mice (I, Table 
1). A number of these genes have a role in skin, and among the most interesting genes are 
matrix metalloproteinases 3 and 13 (Mmp3, 13), betacellulin (Btc), tumor necrosis factor 
receptor superfamily member 6 (Tnfrsf6), alpha-induced protein 2, procollagen, type III, 
alpha 1 (Col3a1) and calmodulin 4 (Calm4). The gene showing the most consistent 
upregulation in all 8 transgenic mice was keratinocyte differentiation association factor 
(Krtdab) with almost four-fold increase in expression. Several keratin-associated proteins 
and hair keratins, S100 Ca-binding protein A3 (s100a3) and fibroblast growth factor 5 
(Fgf5) were highly significantly downregulated in transgenic mice. Among less 
significantly downregulated genes were cathepsin E, small proline-rich protein 2H (sprr2H) 
and desmocollin 2.  
1.4.2 Differential expression between transgenic lines (I)  
 
To highlight the functional differences caused by CCHCR1*WWCC risk allele in 
comparison to normal CCHCR1 allele, expression profiles between the two transgenic mice 
group were compared.  
 
Fifty-six genes were at least two-fold and 14 genes at least three-fold upregulated in risk 
mice as compared to non-risk mice (I, table 2). The highest upregulations were seen with 
several small proline-rich proteins (1B, 2A and 2D), keratin 6a (Krt2-6a) and its partner 
keratin 16 (Krt1-16) and Janus kinase 2 (Jak2). Less upregulated genes included for 
example tenascin C, interleukin 6, Caspase 6 and small proline-rich proteins 2H and 2F 
(Sprr2H, 2F). Among interesting genes shown to be upregulated by t-test-based analyses 
(p<0.001) were trans-acting transcription factor 4 (Sp4), small proline-rich proteins 2F and 
1B (Sprr2F, 1B), zinc finger protein regulator of apoptosis and cell cycle arrest (Zac1), 
defensin beta1 (Defb1) and keratin 6a (Krt2-6a). 
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Also  a  significant  number  of  genes  were  downregulated  in  the  risk  mice  as  compared  to  
non-risk mice: 83 genes were downregulated at least two-fold and 16 genes showed at least 
three-fold  difference  in  expression  (I,  table  2).  Among  the  downregulated  genes  were  
several keratin-associated proteins and acidic hair keratin 5 (Krt1-24). Among less 
significantly downregulated genes were type I hair keratin (Krt1-1), basic hair keratin 5 
(Krt2-18), cytokeratin 19(Krt1-19), matrix metalloproteinase 12 (Mmp12) and S100 Ca 
binding protein A3 (s100a3). With the t-test, the following genes showed significant 
downregulation (p<0.001): cadherin 3 (Cdh3), AP-1 beta subunit (Ap1b1), S100 Ca 
binding protein A13 (s100a13), cadherin 1 (Cdh1), IL-6 signal transducer (Il6st), ubiquitin 
C (Ubc) and S100 Ca binding protein A10 (s100a10). 
1.4.3 Pathway and cluster analysis of gene expression differences (I) 
 
The changes in the expression of the genes participating in different psoriasis-associated 
signaling pathways were studied with Biocarta net tools. Signaling pathways studied 
included NF-kB signaling, keratinocyte differentiation, EGF, TGF-beta and IFN-gamma 
signaling pathways, cytokines and inflammatory response, cell-to-cell adhesion, and 
cytoskeleton organization and biogenesis. With t-test value p<0.01, significant changes 
were detected in the cytoskeleton organization and biogenesis pathway, in which keratins 
6a (Krt2-6a) and 16 (Krt1-16) and alpha 2 actin were upregulated in the risk mice compared 
to non-risk mice. 
 
Similarity  of  gene  expression  patterns  was  studied  by  cluster  analyses.  In  addition  to  the  
usage of the entire expression data, keywords such as integrin, interleukin, transcription 
factor, proteinase, binding protein, protease or keratin were used for subgrouping the data 
for the cluster analyses. To exclude possible differences caused by hormonal background, 
we limited analyses to male mice only. Among seven two-way cluster tree studies, only the 
keratin group with 57 transcripts, representing 37 genes, showed clearly distinct gene 
clusters and the separation among risk, non-risk and wild-type mice was pronounced (I, fig. 
3). Keratin-related genes were divided into two main groups: 20 genes showed higher 
expression levels in risk mice when compared to the non-risk or wild-type mice, and 14 
genes showed lower expression levels in risk mice. One interesting gene is keratinocyte 
differentiation-associated protein (Krtdap), which was differentially expressed according to 
the CCHCR1 genotype. It was upregulated in risk mice as compared to non-risk mice and 
downregulated in wild-type mice. Keratin 5, keratin 6a and keratin 17 expression was 
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higher in risk mice as compared to either non-risk or wild-type mice. Most genes showing 
lower expression level in risk mice belonged to hair keratins or keratin-associated proteins 
expressed mainly in hair. The independent clustering profiles of keratin-related genes, 
between the risk and other mice types, suggest the importance of these genes in classifying 
the different mouse groups and it also promoted the distinct functional aspects between the 
normal and psoriasis-associated CCHCR1 alleles. 
 
2. Functional Studies of CCHCRI 
2.1 CCHCR1 localization in cells (II) 
 
The cellular localization of both normal and psoriasis-associated forms of CCHCR1 was 
studied in transfected cells. Both forms of CCHCR1 showed punctate staining signals in 
the cytoplasm (II, fig. 3a and d). The exact nature of the CCHCR1-containing structures 
remained unclear. CCHCR1 did not co-localize with the endosomal proteins, including 
early endosomal autoantigen 1, the late endosomal protein MLN64 or transferrin receptor 
which localizes to recycling compartments, or with the lysosomal marker Lamp1 or 
mitochondria  (II,  fig.  3i).  In  an  experiment  with  a  fluid-phase  tracer,  CCHCR1-GFP  
positive structures were not accessible to endocytosed dextran. As CCHCR1 was shown to 
play a role in steroidogenesis, we also studied whether CCHCR1 was present in lipid 
droplets. As studied by the neutral lipid stain Nile Red, CCHCR1 did not co-localize with 
lipid droplets (II, fig. 3l). In addition, the CCHCR1 structures did not sequester either with 
filipin, indicating distribution of free cholesterol or NBD-cholesterol detecting the lipid 
droplets, suggesting that CCHCR1-containing particles were not enriched with 
unesterified cholesterol. We did not observe any obvious differences between the non-risk 
and risk forms of CCHCR1.  
2.2 CCHCR1 regulation studies (II) 
 
We also studied the expression levels of CCHCR1 in keratinocytes derived both from 
healthy skin (n = 3) and non-lesional psoriatic skin (n = 4) (Karvonen et al. 2000)  with 
quantitative  real-time  PCR  (TaqMan).  Interestingly,  the  expression  of  CCHCR1  was  
downregulated two-fold in non-lesional psoriatic keratinocytes as compared to normal 
keratinocytes (p  0.05), suggesting the dysregulation of CCHCR1 in psoriatics (II, fig. 
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5a). Expression levels of CCHCR1 did not differ according to the CCHCR1 genotype, but 
the sample size was too small to draw firm conclusions on genotype specific-effect.  
 
In addition, we wanted to study the regulation of CCHCR1 expression. For that purpose 
we treated HaCaT keratinocytes with several growth factors, hormones and anti-psoriatic 
agents and measured the mRNA expression levels with quantitative real-time PCR. The 
highest change in the expression level with almost three-fold upregulation was observed 
after insulin treatment. Estrogen and forskolin (with p-value 0.06) also upregulated 
CCHCR1 by 50%, whereas the immunosuppressant cyclosporin A downregulated 
CCHCR1 expression by two-fold. Dihydrotestosterone (Stanolone) or thyronine did not 
affect CCHCR1 expression on mRNA levels (II, fig. 6b). The effect of epidermal growth 
factor (EGF) on CCHCR1 expression on the protein level was also investigated. The level 
of endogenous CCHCR1 protein in HaCaT cells was too low to be detected by western 
blotting from total cell lysate, but after treatment with EGF, a faint band corresponding to 
the size of CCHCR1 was observed, suggesting EGF as a stimulator of CCHCR1 
expression (II, fig. 6c). Interestingly, cholesterol metabolism also affects CCHCR1 
expression. When cholesterol was depleted from HaCaT keratinocytes by cholesterol 
extraction with 7.5 mM methyl- -cyclodextrin (M CD) and neosynthesis inhibition with 
10 M lovastatin (Jans et al. 2004) CCHCR1 expression showed five-fold downregulation 
(II, fig. 6a). The downregulation was smaller if the neosynthesis was not prevented. 
 
2.3 The role of CCHCR1 in keratinocyte proliferation and migration 
2.3.1 Wound healing in transgenic mice expressing CCHCR1 (III) 
 
Wounding can trigger formation of a psoriasis plaque according to Koebner‘s 
phenomenon and it has also been shown to cause psoriasis-like phenotypes in transgenic 
psoriasiform mouse models (Sano et al. 2005a; Zenz et al. 2005). To study the effects of 
wound healing in the bitransgenic CCHCR1 mice, circular full-thickness 5 mm diameter 
wounds on the dorsal skin on both wild-type and transgenic CCHCR1 mice 
overexpressing either healthy or psoriasis-associated alleles of human CCHCR1 were 
conducted. Mice were sacrificed 1, 4, 11 and 30 days post-wounding, the wound areas 
were measured and wound samples were collected for further analyses so that 8 wounds 
from each mouse group were studied at each time point. Measurements showed that early 
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wound closure at days 1 and 4 post-wounding was delayed in risk mice when compared to 
wound closure in non-risk mice (day 1, p < 0.01 and day 4, p < 0.05) (III, fig. 1A). 
Macroscopic measurement results were supported by histological evaluation and 
measurement  of  the  newly  formed  epithelium  (III,  fig.  1B,  C  and  D).  Interestingly,  the  
epithelial layer was still absent from the wounds in risk mice 4 days post-wounding, 
whereas in non-risk mice, neoepidermis was visible already on day 1 and 50 % of the 
wounds were completely re-epithelializated on day 4. Wound closure and regeneration of 
epidermis was completed in all mouse groups at day 11. No clinical or histological 
features of psoriasis development were observed in the wounded areas during the 30 days 
observation period. 
 
To determine the underlying factors causing the delayed wound closure in risk mice, 
wounds were histologically evaluated. Evaluation of dermal components according to the 
modified Greenhalg criteria (Spenny et al. 2002; Puolakkainen et al. 2005) did not indicate 
any abnormalities in inflammation, formation of granular tissues or neoangiogenesis. As 
these results rule out the dermal components as the primary defect causing the delayed 
wound closure, they suggest that the primary cause of retarded healing might be impaired 
regeneration of the epidermis, which involves proliferation and migration of keratinocytes. 
The migratory properties of keratinocytes were studied with laminin-5 staining (Pyke et al. 
1994) and the apoptosis with TUNEL staining, but they failed to show differences between 
the mice groups. Neither staining of mast cells nor immunohistochemical analyses of 
hyperproliferation marker cytokeratin 6, myofibroblast marker -smooth muscle actin and 
von Willebrand factor, a marker of neoangiogenesis, did reveal any abnormalities in 
transgenic mice. Staining with the proliferation marker Ki67 showed that one day after 
wounding only a few proliferating keratinocytes were found at the wound edges and there 
were no differences between the mouse groups. However, on day 4 the risk mice had 
significantly fewer proliferating cells in newly formed epidermis than wild-type or non-risk 
mice (p < 0.001) (III, fig. 1E). A similar effect was also seen 11 days post-wounding 
(p=0.01) and the same trend was seen even 30 days after the wounding. This highly 
significant difference suggested impaired keratinocyte proliferation as the underlying defect 
causing delayed wound closure in transgenic mice with CCHCR1*WWCC risk allele. 
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2.3.2 Single dose TPA application of transgenic CCHCR1 mice (III) 
 
12-O-tetradecanoylphorbol-13-acetate (TPA) is a chemical used to trigger psoriasis-like 
phenotype in mouse models (Sano et al. 2005a). In order to induce epidermal hyperplasia, 
the dorsal skin of transgenic CCHCR1 and wild-type mice were treated once with topical 
TPA application. Skin samples for histological analyses were collected 24, 48 and 72 h 
after the treatment. All mouse groups showed epidermal thickening 24 h after the treatment. 
However, there were interesting differences between the mouse groups as the TPA-treated 
transgenic CCHCR1 mice showed a less well-developed epidermal hyperplasia than the 
wild-type controls, and the difference was most evident 48 h after the treatment when the 
number of proliferating cells, as indicated with Ki67 staining, was 20-30% lower in 
transgenic mice than in wild-type mice (III, fig. 2A and B). The CCHCR1*WWCC allele 
mice had 14 % fewer proliferating cells than the non-risk mice (p < 0.05) (III, fig. 2D). The 
location of proliferating cells was also different, in transgenic mice proliferating cells were 
confined mainly to the basal layer in epidermis, whereas in wild-type mice proliferation 
was observed also suprabasally (III, fig. 2C). There were no differences in keratinocyte 
differentiation between the mouse groups as indicated by the uniform expression of the 
differentiation marker cytokeratin 10, and also the number of infiltrating T cells was 
indistinguishable between the mouse groups. 
2.3.3 Cell proliferation in untreated mouse skin and cultured keratinocytes of CCHCR1 
mice (III) 
 
In addition to the study of CCHCR1 functional aspects in response to different kinds of 
treatments,  we  wanted  to  study  the  effects  of  CCHCR1  on  normal  keratinocyte  
proliferation. To study cell proliferation, bromodeoxyuridine (BrdU) was injected 
intraperitoneally into the wild-type and transgenic CCHCR1 mice, skin samples were 
collected after an incubation period and BrdU-labeled cells were detected by 
immunohistochemistry. Interestingly, after 6 h labeling time the proportion of BrdU 
positive cells was 63% in the risk allele mice and 77% and 73% in the non-risk allele and 
wild-type mice, respectively. Observed differences suggested impaired cell proliferation in 
risk mice as compared to the non-risk mice (n=4, p < 0.05) (III, fig. 3). A similar trend was 
also seen with Ki67 staining of transgenic mice skin samples (n=3).  
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The impact of transgenic CCHCR1 and its different gene forms on the proliferation rate in 
response to EGF was studied also in cultured keratinocytes derived from newborn 
transgenic CCHCR1 or wild-type mice. Cells were labeled at different time points with 
BrdU  in  the  presence  or  absence  of  EGF.  The  amount  of  incorporated  BrdU  was  
determined with ELISA. The measured absorbance values were plotted as a function of 
time, and relative proliferation rates were estimated from the slope of the line (III, fig. 3B 
and C). The relative proliferation rate was slower in keratinocytes expressing the risk allele 
of CCHCR1 when compared to wild-type keratinocytes, both in the presence or absence of 
EGF. However, no obvious difference in proliferation rate between cells expressing the risk 
allele and non-risk allele of CCHCR1 was observed.  
 
In addition to the effects of CCHCR1 and its different genotypes on proliferation, we have 
also studied keratinocyte migration with newborn transgenic and wild-type mice. Migration 
properties were studied with the Transwell chambers or an in vitro scratch assay (Matthay 
et al. 1993; Cha et al. 1996). We also used a recently described skin explants model to 
study the radial outgrowth of mouse epidermis (Lu&Rollman 2004; Mirastschijski et al. 
2004). These experiments showed that the different alleles of CCHCR1 did not affect the 
migration of keratinocytes. 
2.4 CCHCR1 in steroidogenesis  
2.4.1 Expression of human StAR in skin (II) 
 
CCHCR1 has been shown to induce steroidogenesis by interacting with the StAR protein 
(Sugawara et al. 2003). Even though skin is defined as a steroidogenic tissue, the 
expression of StAR protein has not been reported in skin. We studied StAR expression 
with RT-PCR from cultured human primary keratinocytes and HaCat cells and 
interestingly, StAR mRNA was observed from both cell types (II, fig. 1a). StAR protein 
expression was detected in normal healthy epidermis by immunostaining (II, fig. 1a) and 
its expression was confined to basal keratinocytes, in the same area as CCHCR1 
expression (II, fig 1b). In non-lesional psoriatic skin these two proteins were expressed in 
the basal keratinocytes (II, fig. 1e and f). CCHCR1 and StAR were expressed in the same 
regions in various steroidogenic tissues, including testis and adrenal glands (II, fig. 1g, h, I 
and j). In lesional psoriatic skin, CCHCR1 and StAR expression was detected only in 
partially overlapping areas as StAR expression was most abundant in basal keratinocytes 
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of the rete ridges (II, fig 1c) and CCHCR1 was expressed in keratinocytes above dermal 
papillae (II, fig. 1d; Asumalahti et al. 2002; Suomela et al. 2003). However, when the 
localization  of  CCHCR1  and  StAR  was  studied  in  transfected  cells,  surprisingly  only  a  
minority  of  CCHCR1 signals  was  overlapping  with  StAR protein  (II,  fig.  3).  The  StAR 
antibody  used  did  not  cross-react  with  the  StAR  homolog  MLN64,  as  indicated  by  the  
negative placenta staining (Stocco et al. 2005). In conclusion, according to our study, 
StAR is expressed in the same areas as CCHCR1 in normal human skin and steroidogenic 
organs and the expression pattern is disturbed in lesional psoriatic skin where they show 
an inversed expression pattern.  
 
The expression level of StAR and P450scc was also studied in both healthy and non- 
lesional cultured primary human keratinocytes. Both genes were expressed in 
keratinocytes (II, fig. 5b) and there was no difference in the expression level between 
keratinocytes derived from healthy or psoriatic persons. Interestingly, P450scc 
upregulated five-fold after cAMP-mediated stimulation caused by forskolin, whereas the 
StAR expression level remained unchanged (II, fig. 5b). This supported the previous 
observation about the cAMP-independent regulation of StAR expressions observed in 
other steroidogenic tissues to be valid also in keratinocytes (Mamluk et al. 1999). 
2.4.2 Functionality of CCHCR1 in steroidogenesis (II) 
 
CCHCR1 has been shown to enhance pregnenolone production in cultured cells 
(Sugawara et al. 2003). To further study the function of CCHCR1 and its psoriasis-
associated CCHCR1*WWCC form in steroidogenesis, COS-1 cells were transfected with 
the F2-system encoding other enzymes needed for the reaction (Pollack et al. 1997), StAR 
plasmid and the risk or non-risk form of CCHCR1. The amount of pregnenolone produced 
by COS cells was determined by mass spectrometry. Interestingly, during the 24 h and 48 
h sampling periods, the risk form of CCHCR1 enhanced pregnenolone production as well 
as  the  non-risk  CCHCR1  (II,  fig  2).  The  increment  in  the  amount  of  pregnenolone  was  
similar to that reported previously for CCHCR1 (135%) (Sugawara et al. 2003). 
2.4.3 Steroidogenic genes in transgenic CCHCR1 mice (II) 
 
The previous Affymetrix expression profiles of genes related to steroid or sterol 
metabolism were further analyzed. A comparison of 8 transgenic mice (including both 
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genotypes) and 3 wild-type mice showed 3 relevant genes with clear differences in the 
expression. The most significant change with a 3.8 fold downregulation in transgene mice 
was observed in the expression of vitamin D receptor gene (Vdr). In addition, two-fold 
downregulation in transgenic mice with less significance was observed for NaD(P)-
dependent steroid dehydrogenase (Nsdl) and sulfotransferase 2B1 (Sult2B1). 
2.5 CCHCRI and Vitamin D (II) 
 
As the Vdr gene was differently expressed between transgenic and wild-type mice in 
previously conducted Affymetrix analyses, we wanted to study the expression of vitamin 
D receptor more carefully. Vdr expression was also almost four-fold downregulated in 
cultured keratinocytes derived from risk mice when compared to the Vdr expression in 
non-risk mice (II, fig. 4). We also studied the expression of human VDR in non-lesional 
psoriatic keratinocytes. Interestingly, the VDR gene expression was downregulated in 
non-lesional psoriatic keratinocytes four-fold at mRNA level as compared to normal 
keratinocytes (p = 0.01) when analyzed by quantitative RT-PCR (II, fig. 5a). The 





Even though psoriasis is a common skin disease affecting more than 2% of the population, 
its molecular level pathogenesis is still poorly understood. A main problem in psoriasis 
research is its multifactorial etiology with multiple genes involved. The role of PSORS1 in 
the  etiology  of  psoriasis  is  without  doubt  and  is  the  strongest  genetic  determinant  of  
psoriasis. Despite the convincing amount of research, the identity of the PSORS1 gene still 
remains  unknown  and  the  debate  about  the  exact  genomic  localization  of  PSORS1  gene,  
and  the  presence  or  absence  of  the  candidate  genes  HLA-C,  CDSN  and  CCHCR1  at  the  
most significant area, has been intense (Asumalahti et al. 2000; Nair et al. 2000; Veal et al. 
2002; Holm et al. 2003; Helms et al. 2005; Chang et al. 2006; Zhang et al. 2009). A recent 
large genome-wide association study located the PSORS1 gene to the region flanked by 
HLA-C and CCHCR1 gene (P < 10-150 ) and according to the study, CDSN is outside the 
area  of  strongest  association  (Zhang  et  al.  2009).  This  study  is  one  of  the  first  PSORS1  
studies conducted with non-Caucasian populations and it interestingly transfers the area of 
the strongest PSORS1 association towards CCHCR1, away from HLA-C. Another 
noteworthy fact is that of the SNPs showing the best association, only one is coding, and it 
is the SNP coding the first arginine tryptophan change in the CCHCR1*WWCC allele. In 
addition to the uncertainty of the PSORS1 gene, the lack of good mouse models has also 
hindered psoriasis research, although recently many good mouse models representing 
notable numbers of psoriatic features have been introduced.  
 
1. Gene expression profile of CCHCR1 mice 
 
The role of CCHCR1 and its psoriasis-associated allelic form CCHCR1*WWCC was 
studied in transgenic mice overexpressing both CCHCR1 gene forms under the K14 
promoter, targeting expression to basal keratinocytes. Skin of the mice was normal and 
indistinguishable between the two transgenic mouse groups. However, gene expression 
profiling suggests that CCHCR1 affects the expression of numerous genes relevant for 
psoriasis and showing altered gene expression in human psoriatic skin. Mouse models also 
suggested that CCHCR1 has allele-specific effects on the expression of genes implicated in 
psoriasis. For example, cytokeratins 6 and 16 which are upregulated in human psoriasis 
(Bowcock et al. 2001) were also upregulated in risk allele mice as compared to non-risk 
mice. The highest upregulation in transgenic risk allele mice was observed for small 
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proline-rich proteins (Sprr) 1B, 2A and 2D. SPRRs are precursor proteins for the cornified 
envelope (Backendorf&Hohl 1992) which are induced during the keratinocyte 
differentiation, and for example, SPRR2A and 1B are upregulated in human psoriatic skin 
(Bowcock et  al.  2001).  The  localization  of  the  human SPRR gene  cluster  in  the  PSORS4 
locus also makes them interesting in the context of psoriasis. Interestingly, members of the 
S100 protein family, including S100a3, a10 and a13, were downregulated in risk allele 
mice. The S100 genes are calcium-activated signaling proteins known to be involved in 
keratinocyte differentiation and the pathogenesis of psoriasis (Bowcock et al. 2001; 
Broome et al. 2003; Nukui et al. 2008). Interestingly, a number of human S100 genes are 
also located in the PSORS4 locus. Members of both S100 and SPRR gene families are 
regulated  via  Jun/AP-1  signaling,  which  make  them  even  more  relevant  for  the  
pathogenesis of psoriasis, as the Jun signaling is an important regulator of keratincyte 
differentiation and proliferation (Zenz&Wagner 2006). The allele-specific effects of 
CCHCR1 were also highlighted by the cluster analysis in which the keratin-related genes 
showed remarkable genotype-specific expression profiles: the profile of risk mice diverged 
clearly from the profile of non-risk mice, which for one showed high similarity to 
expression profiles of wild-type mice. Interestingly, “keratin” was the only keyword 
showing allele-specific expression patterns as for example “integrin”, “interleukin” or 
“transcription factor” failed to show any allele-specific patterns. Transgenic mice 
overexpressing the psoriasis-associated or the non-risk form of human CCHCR1 were the 
first mouse models for a psoriasis susceptibility gene mapping to a confirmed locus. In 
addition, they are the first models so far expressing, in addition to the non-risk human gene 
form, also the psoriasis-associated form of a putative susceptibility gene 
 
2. The role of CCHCR1 in proliferation 
 
As the skin of the transgenic mice was indistinguishable from wild-type mouse skin, we 
wanted to test if introducing additional environmental challenges, including wounding and 
TPA treatment, would give rise to psoriasis-like features or differences between the mouse 
groups. CCHCR1 mice did not develop characteristics typical for psoriasis but the results 
obtained from the experiments suggested that CCHCR1 may play a role in keratinocyte 
proliferation. Early wound closure was delayed in the risk mice (III). The mechanism for 
the impaired wound healing was the smaller number of proliferating keratinocytes in risk 
mouse  epidermis  as  compared  to  either  the  normal  transgenic  or  wild-type  mice.  The  
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response to TPA-induced hyperplasia was also impaired in risk allele mice as all the mice 
groups responded to TPA, but the hyperplasia was less well-developed in risk mice and 
they also had fewer proliferating cells. As the CCHCR1*WWCC allele mice showed 
impaired keratinocyte proliferation in response to external stimuli, also its possible effect in 
untreated mice was studied. Indeed, CCHCR*WWCC affected keratinocyte proliferation 
also in native circumstances as revealed by in vivo BrdU labeling  of  untreated  mice:  risk  
allele mice had less proliferating keratinocytes than non-risk or wild-type mice. One can 
conclude that the overexpression of CCHCR1*WWCC resulted in reduced keratinocyte 
proliferation, which is highly relevant in the context of the pathogenesis of psoriasis. 
  
A potential role in one of the most important aspects of psoriasis pathogenesis is highly 
interesting and offers a possible mechanism for CCHCR1 to impact the development of 
psoriasis. In addition to experimental mouse data, other properties of CCHCR1 also 
supported its role in the regulation of keratinocyte proliferation. We have shown in our 
earlier studies that CCHCR1 is expressed at the sites that are less active for cell 
proliferation in psoriatic skin (Asumalahti et al. 2002; Suomela et al. 2003). A similar 
phenomenon has also been seen in breast and lung carcinomas in which CCHCR1 was 
expressed in nonproliferating cells (Suomela et al. 2003). The amount of CCHCR1 protein 
may also be critical for the proliferation and pathogenesis of psoriasis. This is supported by 
the observation that CCHCR1 expression was downregulated in cultured non-lesional 
psoriatic keratinocytes when compared to healthy keratinocytes. However, this 
downregulation has not been observed in our previous in vivo in situ experiments with 
lesional psoriatic skin. This may reflect differences between in vivo and in vitro 
experiments. Furthermore, the samples were different as the in situ results were gained 
from lesional psoriatic skin and the qRT-PCR analyses were done with cultivated non-
lesional keratinocytes. Also the altered expression of the psoriasis hyperproliferation 
markers K6, 16 and 17 in transgenic CCHCR1 risk mice, as compared to either non-risk or 
control mice, shown by expression profiling, supports the potential involvement of 
CCHCR1 in cell proliferation (I). Our regulation studies also supported the CCHCR1 
involvement in proliferation, as agents involved in the regulation of proliferation, including 
interferon , insulin, EGF and estrogen, affected the levels of CCHCR1 expression (II; 
Suomela et al. 2003) . 
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3. CCHCR in steroidogenesis 
 
CCHCR1 has been shown to promote steroidogenesis via interaction with the StAR protein 
(Sugawara et al. 2003) and based on our immunohistological localization data, this may 
also occur in skin. We also demonstrated that the psoriasis risk allele showed similar 
activity in steroidogenesis as the non-risk form. Steroid hormones have a number of 
important functions in skin, of which many are highly relevant also in the context of 
psoriasis. Steroid hormones are required for cell proliferation, epidermal barrier 
homeostasis, differentiation and modulation of immune response (Zouboulis&Degitz 2004; 
Bikle et al. 2005). Interestingly, some skin diseases are also directly caused by inborn errors 
of cholesterol or steroid metabolism. For example, X-linked ichtyosis (OMIM 08100), 
characterized by epidermal hyperkeratosis, is caused by mutations in the steroid sulfatase 
gene (Shapiro et al. 1989). Steroid hormones can also have an effect on the disease course 
of skin diseases, as for example estrogen modulates symptoms of psoriasis 
(Kanda&Watanabe 2005; Murase et al. 2005). Skin and keratinocytes are actively involved 
in steroidogenesis, as all the essential enzymes and cofactors of the steroidogenic cascade 
are present in skin (Venencie et al., 1999; Thiboutot et al. 2003).  
 
Steroid hormones are synthesized from cholesterol in the mitochondria. The first step of the 
synthesis is the conversion of cholesterol to pregnenolone by the cytochrome P450 side 
chain cleave (P450scc) enzyme in the inner mitochondria membrane. Pregnenolone is 
further converted to progesterone and then to a variety of other steroids. The spectrum of 
the final products is defined by the tissue specific enzyme assortment. StAR protein 
participates in and regulates the transportation of cholesterol from the outer mitochondria 
membrane to the inner membrane to be available for P450scc. StAR is expressed in steroid-
producing tissues (Stocco et al. 2005) and interestingly according to our results, StAR is 
expressed  also  in  the  basal  keratinocytes  of  the  skin.  In  healthy  human  epidermis,  StAR  
expression was confined to the areas where also CCHCR1 expression was most abundant. 
StAR expression was altered in psoriatic skin and the expression pattern also varied 
between the non-lesional and lesional psoriatic skin. In non-lesional psoriatic skin, StAR 
expression was inverse compared to CCHCR1 expression. In addition to interaction with 
StAR, agents relevant in steroidogenesis affected the expression of CCHCR1, supporting 
the connection between CCHCR1 and steroidogenesis. Interestingly, cholesterol, the 
substrate of steroid hormones, affected the expression of CCHCR1 in keratinocytes, as the 
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amount  of  CCHCR1  decreased  5-fold  after  cholesterol  depletion.  Deficient  cholesterol  
metabolism causes alterations to keratinocyte differentiation. Furthermore, cholesterol 
depletion influences the expression levels of a variety of differentiation marker genes (Jans 
et al. 2004). In addition to cholesterol, other factors also relevant in steroidogenesis 
influence CCHCR1 expression. For example, epidermal growth factor (EGF) and insulin-
like growth factor (IGF) are known activators of steroidogenesis (Stocco et al. 2005) and 
also stimulate CCHCR1 expression. Also, the steroid hormone estrogen stimulates 
CCHCR1 expression as well as forskolin, a known steroidogenesis activator. Based on the 
StAR interaction and expression data, it appeared well justified to conclude that CCHCR1 
is connected to steroidogenesis. Skin is a steroidogenic tissue and thus able to produce 
steroid hormones locally. Locally produced steroids can be highly important for psoriasis as 
they may participate, for example, in the regulation of cell proliferation, differentiation and 
immune response (Bikle et al. 2005; Lehmann 2005). Defects in steroidogenesis are likely 
to impact on the pathogenesis of psoriasis as indicated also by the altered StAR expression 
observed in psoriatic skin. As CCHCR1 promotes steroidogenesis and the knockdown of 
CCHCR1 with RNA interference reduces the amount of pregnenolone in cultured 
steroidogenic cells (Sugawara et al. 2003), CCHCR1 seems to have a definite role in the 
synthesis of steroid hormones. CCHCR1 may influence steroidogenesis via regulation of 
StAR. The low CCHCR1 level observed in psoriatic keratinocytes may also be relevant, as 
the amount of CCHCR1 may affect the efficiency of steroidogenesis. Taken together, it is 
reasonable to conclude that CCHCR1 may influence local steroidogenesis in skin and by 
that it may affect processes relevant for the pathogenesis of psoriasis. 
 
Our results suggest that CCHCR1 may also have a role in skin vitamin D metabolism, 
which is highly interesting in the context of psoriasis. Vitamin D is a steroid hormone that 
regulates  keratinocyte  proliferation  and  differentiation,  as  well  as  formation  of  the  
epidermal barrier (Reichrath 2007). It is also successfully used as a treatment for psoriasis 
(Schauber&Gallo 2008). In addition, vitamin D receptor (VDR) polymorphisms have been 
suggested to associate with psoriasis (Saeki et al. 2002; Halsall et al. 2005; Dayangac-
Erden et al. 2007) and the level of VDR has been proposed to affect the responsiveness to 
vitamin D therapy in psoriasis patients (Carlberg&Saurat 1996). According to our study, 
the vitamin D receptor is expressed by keratinocytes and its expression is decreased in non-
lesional psoriatic keratinocytes. Also the Vdr expression in CCHCR1*WWCC risk allele 
mice was downregulated when compared to transgenic mice with normal CCHCR1 or wild-
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type animals. This genotype-specific effect suggested an impaired function for the 
CCHCR1 risk form in vitamin D metabolism, and as the level of VDR is known to affect 
the response to vitamin D treatment, this altered VDR level is important to consider. 
 
Keratinocytes appear as a central cell type in skin steroidogenesis and vitamin D 
metabolism, as they express both StAR and P450scc, the key enzymes of steroidogenesis. 
In addition to cholesterol, P450scc enzyme also metabolizes vitamin D3 and its precursor 
7-dehydrocholesterol (7-DHC) found mainly in basal epidermal keratinocytes (Slominski et 
al. 2004). Indeed, keratinocytes are the only cell type that has the entire metabolic 
machinery to produce the active form of vitamin D from 7-DHC and in addition has 
receptors for it. The P450scc-metabolized vitamin D forms also affect keratinocyte 
differentiation and their effects are mediated via VDR.  
 
4. Biochemical pathways of CCHCR1 function 
  
CCHCR1 has a role in the proliferation of keratinocytes but the mechanisms still remain 
unknown. There are a couple of alternatives based on the other functional aspects of 
CCHCR1. One possible mechanism how CCHCR1 could influence keratinocyte 
proliferation involves interaction with RNA polymerase II subunit 3 (RBP3) (Corbi et al. 
2005). RBP3 is a part of the RNAPII core enzyme, which is composed of at least 12 
different subunits. RNAPII associates with several mediator proteins and general 
transcription factors to form the holoenzyme complex, the activity of which is tightly 
controlled by several auxiliary factors in order to confer its proper tissue-specific activity. 
Interestingly, CCHCR1 has been suggested to serve as a cytoplasmic docking site for 
RPB3, regulating its movement from the cytoplasm to nucleus (Corbi et al. 2005). In 
addition to other regulatory proteins, RBP3 also interacts with the activating transcription 
factor 4 (ATF4/CREB2), a member of the ATF family. ATF4 is able to form heterodimers 
with other members of the AP-1 family, including Jun and Fos proteins. Interestingly, Jun 
proteins, namely c-jun, JunB and JunD are among regulators of keratinocyte proliferation, 
differentiation  and  cytokine  production.  It  is  also  noteworthy  that Jun proteins have been 
implicated to have a role in the pathogenesis of psoriasis: expression of JunB, located to the 
PSORS6 locus, is greatly reduced in lesional psoriatic skin (Zenz et al. 2005) and elevated 
c-Jun levels have also been observed in psoriatic skin (Mehic et al. 2005). In addition, the 
double knock-out c-jun/JunB mice spontaneously develop psoriasis-like phenotype (Zenz et 
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al. 2005). Individual members of the AP-1 family have specific functions in cellular 
processes and also the target tissues affect the functional characteristics of AP-1-mediated 
activity (Angel et al. 2001). Jun proteins are activated by Jun-amino-terminal kinases 
(JNKs). The activated c-jun-containing AP-1 complex promotes cell proliferation by 
inducing transcription of positive regulators of cell cycle progression, including cyclin D1 
and suppressing the negative regulators, such as tumor suppressor p53 production 
(Zenz&Wagner 2006). The AP-1 family has also been proposed to be involved in wound 
healing because of its rapid and transient expression kinetics and response to extracellular 
signals. AP-1 activity is supposed to be required under conditions where the balance of 
keratinocyte  proliferation  and  differentiation  is  changed  rapidly  and  temporally,  as  is  the  
case in wound healing (Angel et al. 2001). As CCHCR1 has a clear antiproliferative effect, 
which was most prominent after wounding and TPA treatment, it is tempting to propose 
that CCHCR1 might influence AP-1 signaling through regulation of RPB3 protein. The 
regulation  could  be  dysfunctional  in  psoriasis  due  to  a  lowered  CCHCR1  amount,  as  we  
have shown to be in psoriatic keratinocytes, or the allele-specific alterations caused by the 
CCHCR1*WWCC risk allele. Even though AP-1-mediated regulation is the most important 
regulator of keratinocyte proliferation, additional regulation pathways for the proliferation 
and pathogenesis of psoriasis also exist and their role in the context of CCHCR1 remains to 
be elucidated. 
 
As CCHCR1 is known to activate steroidogenesis via interaction with the StAR protein, 
steroids also offer a possible route for CCHCR1 to influence proliferation. Steroids can 
modulate wound healing in human and mouse skin and may also affect keratinocyte 
proliferation (Urano et al. 1995; Ashcroft et al. 1997; Verdier-Sevrain et al. 2004; Gilliver 
et al. 2006; Gilliver&Ashcroft 2007). Furthermore, vitamin D, a steroid hormone, affects 
keratinocyte proliferation and wound healing (Gurlek et al. 2002; Gamady et al. 2003). The 
effect of CCHCR1 in keratinocyte proliferation may be explained by its role in 
steroidogenesis. This is supported by impaired vitamin D receptor expression in psoriatic 
skin and in CCHCR1*WWCC mice. Interestingly, both vitamin D and estradiols are 
involved in the biology of AP-1, as they both induce the expression of c-fos and c-jun, and 
AP-1 is also a mediator of vitamin D-induced differentiation (Johansen et al. 2004; Verdier-
Sevrain et al. 2004). As vitamin D and its receptor participate in many functions relevant in 
the  context  of  psoriasis  and  CCHCR1  seems  to  have  an  allele-specific  effect  on  the  
expression of vitamin D receptor downregulated in psoriatic skin, this offers an interesting 
68 
functional mechanism for CCHCR1 in the pathogenesis of psoriasis. Possible mechanisms 
could be the regulation of StAR or P450scc, as those are suggested to metabolize vitamin D 
and its precursors from 7-DHC, and StAR is known to interact with 7-DHC (Slominski et 
al. 2004).  
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CONCLUSIONS AND FUTURE PROSPECTS 
 
CCHCR1 seems to affect keratinocyte proliferation and steroidogenesis, functions possibly 
overlapping. Both functions are highly important in the context of the pathogenesis of 
psoriasis. Furthermore, transgenic CCHCR1 mice support a role for the psoriasis-associated 
allele  CCHCR1*WWCC  in  the  pathogenesis  of  psoriasis  as  the  mice  with  the  risk  allele  
showed many allele-specific differences in processes relevant for psoriasis, including 
expression of genes relevant in psoriasis. The downregulation of CCHCR1 in human 
psoriatic keratinocytes for one suggests the possibility that the impaired function of 
CCHCR1 might be explained by its insufficient amount in psoriatic skin. There are 
tempting alternatives for potential mechanisms of CCHCR1 function mediated by AP-1 
signaling steroids. However, the more detailed function of CCHCR1 and the mechanism, in 
which it participates, needs to be elucidated in more detail in the future. 
 
It would be highly interesting to study if the amount of CCHCR1 impacts on its cellular 
functions. The possible effects of CCHCR1 inhibition also deserve to be investigated. In 
addition, as the cellular localization of CCHCR1 still remains unknown, it should be given 
attention in future studies. The research clarifying the allele-specific impact of CCHCR1 
risk and non-risk forms is also highly relevant in order to understand the possible role of 
CCHCR1 in the pathogenesis of psoriasis.  
   
PSORS1 is the major psoriasis susceptibility locus and transgenic CCHCR1 mice were the 
first transgenic mouse model for a candidate gene located in any psoriasis susceptibility 
locus. In addition, CCHCR1*WWCC risk mice are so far the only transgenic mice targeting 
the psoriasis-associated allelic form of a psoriasis candidate gene. CCHCR1 mouse models 
offer an interesting view on the possible role of CCHCR1. However, there are matters to 
take into account concerning the different aspects of the model. The expression level of 
mouse endogenous CCHCR1 is not known, which makes it difficult to evaluate the 
functional impacts of the CCHCR1 transgene in mice. This should also be remembered 
when considering the possible allele-specific effects of the CCHCR1 transgene. In addition, 
when studying multifactorial diseases, it is always possible that the susceptibility gene 
alone is not sufficient to produce the phenotype, as additional genes or environmental 
factors might be needed to trigger the phenotype. One should also perceive the differences 
in the biology of mouse and human skin. As the functional aspects of CCHCR1 have 
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remained mainly unknown, the transgenic CCHCR1 mouse offers novel information of the 
possible role and function of CCHCR1.  
 
As genetic research has failed to convincingly identify the effector gene in the PSORS1 
locus, functional studies are needed to elucidate the individual roles of PSORS1 candidate 
genes and thus facilitate the identification of the PSORS1 gene. Our results support 
CCHCR1 as an important PSORS1 locus gene, as it is a newly recognized regulator of 
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